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                ABSTRACT 
    Biomolecules can easily recognize its corresponding partner and get bound to it, 
resulting in controlling various processes (immune system, inter or intracellular 
signaling) in biology and physiology. Bonding between two partners can be a result of 
electrostatic, hydrophobic interactions or shape complementarity. It is of great 
importance to study these kinds of biomolecular interactions to have a detailed 
knowledge of above mentioned physiological processes. These studies can also open 
avenues for other aspects of science such as drug development.  Discussed in the first part 
of Chapter 1 are the biotin-streptavidin biomolecular interaction studies by atomic force 
microscopy (AFM) and surface plasmon resonance (SPR) instrument. Also, the basic 
working principle of AFM and SPR has been discussed.     
    The second part of Chapter 1 is discussed about site-specific chemical modification of 
peptides and proteins. Proteins have been used to generate therapeutic materials, proteins-
based biomaterials. To achieve all these properties in protein there is a need for site-
specific protein modification.  
    To be able to successfully monitor biomolecular interaction using AFM there is a need 
for organic linker molecule which helps one of the investigating molecules to get 
attached to the AFM tip. Most of the linker molecules available are capable of 
investigating one type of interaction at a time. Therefore, it is significant to have linker 
molecule which can monitor multiple interactions (same or different type) at the same 
time. Further, these linker molecules are modified so that biomolecular interactions can 
also be monitored using SPR instrument. Described in Chapter 2 are the synthesis of 
 ii 
 
organic linker molecules and their use to study biomolecular interaction through AFM 
and SPR.  
    In Chapter 3, N-terminal chemical modification of peptides and proteins has been 
discussed. Further, modified peptides are attached to DNA thread for their translocation 
through the solid-state nanopore to identify them. Synthesis of various peptide-DNA 
conjugates and their nanopore studies have been discussed in this chapter.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Biomolecular interactions monitored by atomic force microscopy (AFM) 
   
   The atomic force microscopy (AFM) is a type of scanning probe microscopy used to 
investigate surface properties with nanoscale resolution.1,2 Scanning tunneling 
microscopy (STM) was the first of the series of probe microscopes, invented by Gerd 
Binnig and Heinrich Rohrer.3 They were awarded Nobel Prize in 1986 for this discovery. 
STM is capable of imaging conducting and semiconducting surfaces, but unable to 
perform the same job in case of non-conducting surfaces. This fact led to the discovery of 
AFM, capable of imaging both conducting and nonconducting surfaces, by Gerd Binnig 
and first commercial AFM was available in 1989.  Other than imaging, one of the 
significant applications of AFM is its ability to measure mechanical properties of the 
biological samples.  
    Studying molecular interactions is of great importance in molecular and structural 
biology. These molecular interactions comprise of forces which include multiple weak, 
non-covalent bonds formed between different interacting portions of molecules. Various 
techniques such as surface force apparatus,4 optical traps, and tweezers,5,6 have been 
developed for past couple of decades to investigate molecular interactions at single 
molecular level. Hige force sensitivities make the optical tweezers popular choice for 
performing experiments, but large sample length and limitation in the amount of force 
applied for the investigation purpose make use of this technique limited. 
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AFM provides a solution regarding both the features. Here are some of the important 
biomolecular interactions monitored by AFM listed below.    
1.1.1 Receptor/ligand interactions   
    Biomolecules can easily recognize its corresponding partner and get bound to it, 
resulting in controlling various processes (immune system, inter- or intracellular 
signaling) in biology and physiology. Bonding between two partners can be the result of 
electrostatic, hydrophobic interactions or shape complementarity. It is of great 
importance to study these kinds of receptor/ligand interactions to have a detailed 
knowledge of above mentioned physiological processes. These studies can also open 
avenues for other aspects such as the development of new drugs. G protein-coupled 
receptors (GPCRs) are one such receptor which remains overexpressed in most of the 
cancer cells.7 Therefore, a ligand attached to an entity having anticancer property can be 
used to target overexpressed receptor for drug delivery. A detailed understanding of 
receptor-ligand interaction is required to make this approach a successful one. One of 
such receptor-ligand interaction studied by AFM is shown here. 
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Luteinizing hormone-releasing hormone (LHRH) receptor, a GPCR, is found to be 
overexpressed in several cancer cell lines. But, it remains absent in healthy human 
visceral organs.8 LHRH is a decapeptide hormone having a binding affinity towards 
LHRH receptor. Therefore, peptides having anti-cancer property can be fused to LHRH, 
and the whole construct can be directed towards overexpressed LHRH receptor in cancer 
cell lines.9 One of such peptides having anti-cancer property is toxic Pseudomonas 
aeruginosa exotoxin 40 (PE40) which is proposed to fuse with LHRH to make anti-
cancer drug conjugate .10 Now, investigation to study the interaction between LHRH-
PE40 and LHRH receptor has been carried out using AFM technique. Also, results have 
Figure 1. A) Schematic representation of LHRH or LHRH-PE40 attached to the AFM tip 
through linker and recptor immobilized over the surface, B) The dependence of 
unbinding force on loading rate for LHRH-PE40/LHRH receptor, C) The dependence of 
unbinding force on loading rate for LHRH/LHRH receptor.10 
  
  (A)   (B) 
  (C) 
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been compared to LHRH-LHRH receptor interaction.10 Schematic diagram for 
performing experiments is shown in Figure 1. 
    Force spectroscopy results revealed that there is no significant difference in the 
dissociation rate constants between LHRH-PE40/LHRH receptor and LHRH/LHRH 
receptor.10 Thus, the fusion of PE40 does not interfere with the recognition and stability 
of LHRH with LHRH receptors. Thus, single molecule force spectroscopy provides us 
with the investigations about kinetics as well as mechanical properties of the ligand. 
1.1.2 Protein/protein interactions   
    Studying protein-protein interactions such as specific antigen-antibody interaction is of 
great importance. AFM has been employed to investigate forces of interactions between 
various antigen/antibody such as antihuman serum albumin (anti-HSA)/ HSA11 and 
antifluorescyl antibody/ fluorescein12. One of the examples shown here is between 
antiferritin antibody and ferritin.11  
 
  (A)   (B) 
Figure 2. Schematic representation of A) ferritin immobilized over the surface, B) 
antiferritin attached to the AFM tip.11 
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Distribution of force histograms revealed that single binding event corresponds to 63pN 
force and increase in force values correspond to the multiple antigen-antibody binding 
events.  
1.1.3 Protein/carbohydrate interactions   
    Affinity of carbohydrate towards lectin is a well-known phenomenon. Studying this 
carbohydrate/lectin interaction is of great importance for developing a new application in 
bioanalytical and biomedical fields.13,14,15,16 Concanavalin A (Conc A) is such an example 
of plant lectins which help in agglutination of erythrocytes and precipitation of glycogen 
  (A)   (B) 
  (C)   (D) 
Figure 3. A) Schematic representation of Conc A immobilized over the gold surface, B) 
structure of thio-terminated hexasaccharide used in the study, C) schematic diagram of 
the experiment, D) histogram of unbinding forces.17 
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and starch from solution through its attachment to α-manosyl and α-gucosyl groups. 
Therefore, monitoring forces of interaction between Conc A and oligo glucose molecule 
would help us to understand detailed mechanisms of above-mentioned processes. Here is 
one such example displayed here to investigate molecular interaction between Conc A 
and hexasaccharide using AFM techniques.17 
    Histogram of unbinding forces reveals that mean value for forces of interaction is 
55pN.17 Two control experiments were carried out. One is monitoring forces of 
interaction between hydroxyl terminated polyethylene glycol molecule, and Conc A. 
Other one is by blocking binding site of Conc A using mannose, followed by studying 
force curves. Both the cases resulted in a very insignificant amount of specific forces of 
interactions. This, in turn, proves forces are originated from the specific Conc A-
carbohydrate interaction. 
1.2 Atomic force microscopy (AFM)  
  
    AFM is a powerful technique which can be used in different fields of science such as 
biology, nanotechnology, surface science for various purposes which include imaging, 
force spectroscopy, recognition imaging. There are a couple of advantages of using AFM 
over other imaging techniques such as Transmission Electron Microscopy (TEM) or 
STM. 
a) For imaging, AFM can work on both conducting and non-conducting surfaces, 
whereas STM needs conducting surfaces. 
b) Experiments can be carried out in air, liquid and vacuum medium using AFM. 
c) AFM is capable of generating three-dimensional images. 
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Other than these above mentioned facilities AFM has some disadvantages too. Slow 
scanning speed and small surface area scanning are two disadvantages of AFM. Still, it’s 
use in force spectroscopy and recognition imaging making it an indispensable tool in the 
field of nanoscience.  
1.2 Working principle   
    The basic configuration of AFM is shown in Fig 4. AFM consists of a cantilever and a 
sharp tip attached to one end of the cantilever. When the tip is brought closer to the 
surface to be analyzed, the interaction between surface atoms and tip atoms cause 
Figure 4. Working principle of AFM. (Adapted from Agilent 5500 manual) 
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deflection in the cantilever. This deflection is further measured by a laser beam falling on 
the back side of a cantilever and getting collected into the photo diode detector.  
This phenomenon occurs based on Hook’s law which says force (F) required to expand or 
contract a spring is directly proportional to the amount of displacement (x) of spring. 
                                                           F α (-x) 
                                                    or,   F= - Kx  [K= spring constant] 
[negative sign indicates direction of spring displacement is opposite to the applied force]  
1.2.1 Different parts of AFM   
Different parts of AFM have been described below. 
AFM probe: 
AFM probe consists of a holder plate carrying a cantilever and tip. The tip is made up of 
Figure 5. An Agilent AFM instrument. (Adapted from Agilent 5500 manual) 
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a silicon or silicon nitride. The radius of the tip is of nanometer diameter and length of 
the cantilever is around 15-30 µm.  
AFM scanner: 
Scanner has a piezoelectric material which helps the scanner to elongate or contract upon 
exposure to the external electric field. This scanner movement, in turn, moves the tip 
along z-direction as it is attached to the scanner. 
  (A)   (B) 
  (C)   (D) 
Figure 6. A) Schematic representation of AFM probe, B) AFM scanner, C) photodiode, 
D) sample plates. (Adapted from Agilent 5500 manual) 
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Detector: 
Detectors consist of photodiodes which collect change in laser spot position equivalent 
cantilever deflection. 
Sample plate:  
It is equipped with a place where surfaces having immobilized sample can be kept. 
Different sample plates are available based on various experimental setup. 
1.2.2 Modes of AFM   
AFM can work in three different modes 
a) Contact mode 
b) Non-contact mode 
Figure 7. Force vs distance curve showing different region of forces during AFM 
experiment.18 
  
 11 
 
c) Tapping mode 
Contact mode 
 In this mode, AFM tip remains in contact with the surface. As tip always remains in 
contact with the surface, there is always a chance of soft biomaterial samples being 
destroyed. So, this mode is not suitable for soft samples. 
Non-contact mode: 
In this mode, the tip does not make any contact with the surface; rather it oscillates at or 
near resonance frequency keeping a fixed distance from the surface. As tip never touches 
samples, this mode is applicable for soft biological samples. But, resolution of images 
obtained from this mode is generally low. 
Tapping Mode: 
In this mode, tip oscillates at or near resonance frequency and makes intermittent contact 
with the surface. This mode is highly popular in taking high-resolution images of soft 
biomaterial sample. 
1.2.3 Force spectroscopy   
    One of the most popular applications of AFM technique is its use to measure the force 
of interaction at single molecular level. To be able to investigate force of interaction 
between two molecules, one has to be immobilized on the surface and another one has to 
be attached to the AFM tip. Now, the tip is brought closer to the surface so that tip makes 
contact with the surface, allowing both the molecules to bind with each other. The tip is 
then retracted from the surface to rupture interactions between the molecules. This 
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rupturing force is called unbinding force which is finally measured by force 
spectroscopy. Now, approach and retraction incidents can be performed several times at a 
particular place or different places over the surface to collect a lot of undinding force 
data, followed by plotting a histogram to get a distribution of unbinding forces. In a force 
curve, the x-axis denotes distance of a tip from the surface and cantilever deflection is 
plotted along the y-axis. 
Figure 8. Force vs distance curve showing different region of forces during AFM 
experiment.19 
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1.3 Surface plasmon resonance as a tool to study biomolecular interaction 
   
    Surface plasmon resonance (SPR) is an optical biosensor technique which helps us to 
study kinetic analysis of biomolecular interaction by detecting refractive index change in 
the close vicinity of the metal surface. Surface plasmons at the metal surface oscillate to 
generate electric field which ranges up to 200 nm above the metal surface and sample 
solution junction.21 Any changes within this range can be monitored to perform the real 
time kinetic analysis between investigating pair of molecules. First commercially 
available SPR was in the market in 1990s.22 Since then it has been used extensively to 
carry out various biomolecular interactions such as protein-protein,23,24 protein-DNA,25,26 
protein-polysaccharides27. SPR has a couple of advantages over other available 
techniques such as fluorescence or enzyme-linked immune-sorbent assay (ELISA). 
Figure 9. Schematic diagram of force-distance cycle including approach and retraction 
curve.20 
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a) There is no need for the analytes to be labeled by fluorescence tags for 
SPR studies. SPR works on detecting changes in refractive index. So, 
the analytes do not require to have any special characteristics. 
b) SPR data can be collected in real time to get kinetic and 
thermodynamic parameters related to the analyte. 
c) Samples tested in SPR can have a high range of molecular weights and 
binding affinity. 
These are the features that make SPR an essential technique to monitor biomolecular 
interactions. 
1.3.1 Working principle   
    Surface plasmons are delocalized conduction electrons present at the interface between 
any two materials (metal/air). These plasmons generate an electromagnatic wave by 
oscillating at a particular frequency. This wave goes in a direction parallel to the metal 
surface. The wave being at the boundary of a conducting surface and external medium, it 
gets disturbed by any changes in the close vicinity of the boundary, such as passing of 
any molecule over the surface. When this metal surface is irradiated with plane polarized 
light at a critical angle, the entire laser light undergoes total internal reflection. Under this 
condition resonance occurs when the frequency of incident photons matches with the one 
from oscillating plasmons, leading to the transfer of the energy from the photon to the 
plasmons. This energy transfer results in the reduction in intensities of reflected light. 
Now, any changes in refractive index close to the metal surface will have a different 
angle at which energy would be transferred. 
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 An example of these two angles is displayed in the fig.10. If changes in laser incident 
angle can be monitored over time, real time kinetic parameters can be derived from this. 
   In a typical SPR experiment, one set of molecules (ligand molecule) is immobilized on 
the metal thin film, and another set of molecules (analyte molecule) is flown over the 
metal film to study molecular interactions. When the analyte molecules reach to the metal 
surface, changes in the refractive index near surface cause a jump in the SPR signal 
  (A) 
  (B)   (C) 
Figure 10. A) Schematic representation of a SPR experiment,28 B) laser intensity vs 
angular shift graph showing dip in laser intensity at two different angles,29 C) a typical 
SPR sensorgram representing ligand-analyte interaction over time.29  
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which is represented as a curve called sensorgram. An example of one such sensorgram is 
shown in fig.10. 
1.3.1 Different parts of SPR   
Diagram of a BI-2000 SPR is shown in fig 10. 
It comprises of a plane polarized light source, a prism, a metal thin film and a 
photodetector.  
Syringe pump: 
For BI 2000 instrument, there is one syringe pump which controls the flow of buffer 
running through the SPR instrument. This syringe pump can accommodate two 10 mL 
syringes. Flow rate, the volume change of buffer in syringes can be adjusted through this 
part of an instrument. During experiments, generally, buffer flow rate through the 
instrument is kept between 30 µL/min - 100 µL/min. 
Valve Tray 
 
Valve tray has three component parts- mode (single and serial) controller, channel 
controller and sample injection area. Different injection loop sizes (100 µL - 1000 µL) 
can be used for SPR experiments.  
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Flow cell and retainer ring 
Flow cell in SPR contains injection gasket. It is made up of polyether ether ketone 
material (PEEK). Dimension of flow cell is 2.8 x 2.0 x 1.4 cm. 
 
Flow injection gasket 
Injection gasket has channels through which buffer solution passes through the waste 
bottle. It is made up of silicone-based elastomer material. 
 
  (A) 
  (C)   (D) 
  (B) 
Figure 11. Diagram of a BI 2000 SPR instrument A) Diagram of different parts of 
SPR instrument B) syringe pump, C) valve tray, D) flow cell and retainer ring 
(Adapted from Biosensing Instrument BI 2000 SPR mannual) 
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1.4 Site-specific chemical modification of peptides and proteins 
 
1.4.1 Importance of protein bioconjugates in biology  
    Proteins, class of large biomolecules comprise of long chain amino acid residues, can 
take part in controlling diverse functions such as catalysis,30 storing energy,31 responding 
to pathogens and neutralize them32. To get a detailed understanding of these functions, 
protein structures are needed to be studied. Recently, proteins have been used to generate 
therapeutic materials, proteins based biomaterials. To achieve all these functional 
properties in protein along with studying its structural aspect, there is a need for site-
specific protein modification. Chemical modification of amino acid side chains started 
way back over 100 years ago and still today search is going on for simple, effective 
bioconjugation strategies. Some of the examples of protein-based material and protein 
polymer conjugates having therapeutic properties have been discussed below. 
Protein-polymer drug conjugate with improved pharmacokinetics   
    Site-specific attachment of polymer chains to protein to improve its pharmacokinetic 
properties have been carried out over the past couple of decades. Use of biocompatible, 
non-immunogenic polyethylene glycol as a polymer chain capable of improving serum 
half-life and stability of a protein is very common.33,34 One such example is shown 
below. 
Poly(oligo(ethylene glycol)methyl ether methacrylate) [Poly(OEGMA)] was attached 
stoichiometrically to the N-terminus of myoglobin (Mb) protein. Mb was first site-
specifically modified to a ketone functional group using biomimetic transamination 
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reaction, followed by attachment of atom transfer radical polymerization (ATRP) initiator 
through imine formation. Next, ATRP of OEGMA was carried out in situ in the buffer. 
Mb and polymer conjugated Mb have been administered intravenously into nude mice to 
monitor pharmacokinetic behaviors of both molecules. Results revealed that Mb has short 
distribution phase and rapid terminal elimination phase compared to Mb-OEGMA 
conjugate.35 
Protein-based material 
    Attachment of synthetic groups to protein leads to a generation of protein-based 
materials where protein functions are still kept intact. This newly synthesized 
biomaterials can be used for various purposes such as building light harvesting devices 
Figure 12. A) Schematic representation of in situ growth of [Poly(OEGMA)] at the N-
terminus of myglobin. B) Stuructures of pyridoxal-5-phosphate (PLP), (2-
(aminooxy)ethyl) 2-bromo-2-methylpropanoate (ABM) and [Poly(OEGMA)].35 
  
  (A) 
  (B) 
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exploiting protein functions.36,37 One example of the protein-based hydrogel is shown 
below. 
 
 
Metallothioneins are conjugated to the polymer formed from polymerization of 
acrylamide monomer, at C- and N-terminus. Now, these conjugated polymers are allowed 
to form hydrogels where proteins will be incorporated inside hydrogels. These hydrogels 
are cut into small pieces and incubated with different metals such as cadmium, copper, 
mercury, zinc, manganese, calcium. Studies revealed that heavy metals cadmium, 
mercury help to reduce the volume of hydrogels due to its ability to bind with proteins. 
Figure 13. A) Schematic representation of hydrogels showing attachment of metals to 
proteins inside hydrogels. B) reaction scheme showing site-specific modification of 
protein at bot N- and C-terminus.38 
  
  (A) 
  (B) 
 21 
 
But, there is no such significant amount of volume change noticed for hydrogels which 
were incubated with non-heavy metals. That is how, this protein-based material is 
capable of recognizing and sequestering toxic heavy metals in presence of large 
concentration of background ions.38 
1.4.1 Traditional methods for chemical bioconjugation 
    The presence of unprotected polar side chains over the protein surfaces makes 
attachment of a synthetic group to a particular position very challenging task. Also, under 
the reaction conditions, proteins have to remain stable. Basically, the reaction has to be 
carried out in mild condition (aqueous media, near neutral pHs, mild temperature). Some 
of the traditional methods for protein bioconjugations are listed below. 
    Amino acids which are targeted for attaching chemical handles are aspartic acid, 
glutamic acid, cysteine and lysine residues. Lysine side chains are susceptible to reaction 
with N-hydroxy succinamide (NHS) ester containing reagents. Cysteines are capable of 
Figure 14. Schematic representation of native amino acid residues in proteins 
undergoing different reaction for attachment of synthetic group.39  
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reaction with maleimide functional group containing reagents. Carboxylic acid groups of 
aspartic acid and glutamic acid can be activated reacting with activating reagent such as 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC).39 
    Issues with these traditional methods are the installation of multiple copies of desired 
synthetic group all over the proteins. This leads to the formation of the heterogenous 
mixture, resulting in a detrimental effect on some of the protein-based bioconjugates such 
as protein-based therapeutic agents.A heterogenous mixture of protein conjugates will 
make pharmacokinetic analysis very challenging. Moreover, indiscriminate attachments 
might lead to modification of active site of a protein resulting in changes in protein 
functional property. To solve these problems, there is always search for chemical 
reactions which selectively install reactive handles at a desired location in protein. 
 1.4.1 Advancement in site-specific bioconjugation 
    Site-specific chemical modification of proteins can be carried out in a single step or 
two steps. A single step will have functional handle directly installed into protein. In two-
step process first, a reactive handle will be site-specifically installed with proteins, 
followed by a bioorthogonal reaction for attaching the desired molecule to the protein. 
Some of the site-specific bioconjugation reactions are discussed below. 
One of the techniques is to target amino acid residue which prevails in lower abundance 
in protein.40 Cysteine is one such amino acid whose one solvent accessible copy can be 
placed into the protein. Using chemical ligation reaction, cysteine derivative can be 
reacted selectively with a C-terminus modified thioester.41,42 Aromatic amino acid 
residues such as tyrosine, tryptophan are also found with intermediate frequency on 
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protein surfaces. These amino acids can be targeted for site-specific chemical 
modification in protein. Some of the examples have been discussed below. 
A tyrosine residue in chymotrypsinogen A was selectively modified by various aldehyde 
compounds in the presence of aniline derivatives at pH 6.5 and 37 0C temperature. Site-
selectivity was confirmed by electrospray ionization mass spectrometry (ESI-MS).43 
Tryptophan residue in horse heart myoglobin was selectively modified by a vinyl diazo 
compound in the presence of rhodium carbenoid at pH 3.5.44 N-terminal tryptophan 
residues can be modified by the pictet-spengler reaction.45 Serin, threonine residues can 
be selectively reacted with a peptidyl glycoaldehyde ester.46 
    Another effective technique for modifying proteins site-selectively is using enzymatic 
labeling. This technique enables us to modify a particular section of protein in protein 
mixture. Scalability is the only problem related to this technique. One of the examples of 
Figure 15. Schematic representation of specific amino acid residues participating in site-
specific chemical modification in proteins.43,44,46 
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this technique is use of formyl glycine enzyme (FGE) to selectively identify aldehyde tag 
(a 6 amino acid sequence) and converts cysteine in that sequence to aldeyde. The 
sequence FGE recognizes is CXPXR (X= serin, threonine, alanine, glycine).47 
Incorporation of unnatural amino acid into protein sequence is one of the successful and 
popular techniques for placing functional groups at any desired location during protein 
expression.48,49 But, complexity of using genetic methods can be one of the disadvantages 
of this technique. That is why, our goal is to develop relatively simple and general one-
step method which can be performed in the aqueous medium at near neutral pH and mild 
temperature to modify protein site selectively. Detailed of this process has been discussed 
in chapter 3.   
 
 
 
 
 
 
 
Figure 16. Schematic representation showing selective modification of cystein residue by 
FGE.47  
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CHAPTER 2 
 
2 Studying streptavidin-biotin interaction using organic linker molecule through 
AFM and SPR 
2.1 Introduction 
 
Organic linkers used to study biomolecular interaction through AFM 
 
    Studying molecular interaction between small organic molecule and biomolecules is an 
important area of research. Most of the targeted drug delivery systems are developed 
based on the interaction between the small molecule and transmembrane receptor.50 AFM 
is one technique which provides us with the opportunities to monitor force of interaction 
between these pairs in piconewton force level. 
…As already mentioned in the first chapter, one of the two investigating molecules has to 
be attached to the AFM tip during force spectroscopy experiment. That can be achieved 
by using organic linker molecule is shown below.  
One end of the linker molecule will get attached to the AFM tip, and another end will 
have investigating molecule attached covalently to the linker. The role of linker molecule 
is paramount to get a high resolution and highly reproducible data. Linker molecule has 
Figure 17. Schematic representation showing attachment of investigating molecule to the 
AFM tip using linker molecule 
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to have a particular criterion to be effective for force spectroscopy. Firstly, there are two 
types of forces recorded, non-specific and specific forces of interaction during force 
spectroscopy measurement. Non-specific originates from the interaction between AFM 
tip and surface, whereas the interaction between two investigating molecules contributes 
to the specific force of interaction. Recording of unbinding specific forces is desired. To 
be able to have distinguished specific forces, linker molecules have to be longer than 
certain lengths. Therefore, the length of the linker molecule is very important during 
force spectroscopy measurement. Secondly, linker molecule has to be stable, rigid and 
robust so that it can maintain its structure during the experiment. Lastly, the flexibility of 
linker is another important criteria because it allows investigating molecule to freely 
orient itself and get bound to the molecule immobilized on the surface. Some of the linker 
molecules used in the AFM studies have reported here. The structure of an organic linker 
molecule having maleimide functional group at one end and N-hydroxyl succinamide 
ester (NHS) group at the other end has been shown below. Maleimide group has been 
used to attach thiolated DNA aptamer, and NHS group has been reacted with its amine 
functional group on the AFM tip. Force spectroscopy studies have been carried out 
Figure 18. Structure of organic linker molecule having maleimide group and NHS 
group.21  
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between DNA aptamer and immunoglobin E (IgE), resulting in 49+18 pN unbinding 
force.21 
    Another linker having NHS group on one end and acetal group on the other end has 
been shown below. NHS group has been attached to the AFM tip and acetal group has 
been reacted with biotin modified immunoglobin G (IgG). Force spectroscopy studies 
have been carried out between avidin and biotin, resulting in 51 pN of unbinding force.51 
    Issues with these linkers are only one type of biomolecular interaction can be 
monitored at a time because only one functional group site is available for the 
biomolecule attachment to the linker. Therefore, there is a need for a linker system 
through which more than one type of biomolecular interaction (same or different type) 
can be monitored. Three arm linker molecule has been proposed to serve this purpose.  
    Other than using three arm linker to improve biomolecular interactions investigation 
through AFM, its structural resemblance to anibody leads us to think of its use as 
antibody mimic.  
 
 
 
Figure 19. Structure of organic linker molecule having acetal group and NHS group.51  
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Three arm linker as antibody mimic 
 
    “Magic bullets”, such as small molecule inhibitors and monoclonal antibodies for 
targeting epidermal growth factor receptors (EGFR), have been developed for the 
treatment of cancer.52 Although great progress in the targeted therapy has been made, 
there is still an absence of effective agents to tackle those proteins encoded by TP53, 
RAS, and MYC genes, where the most common mutations in human cancer take 
place.53,54,55 For comparison, the small molecule drugs can easily access intracellular 
disease targets, but they have notorious off-target toxicities and lack effectiveness to 
block protein-protein interactions56 whereas the antibodies possess high specificity and 
binding affinities to their protein targets, but exhibit poor extravasation and limited tissue 
penetration due to their large size and complexity.57 Based on current knowledge, one can 
envision a new molecular entity that possesses merits of both large and small drugs for 
the discovery of cancer drugs. Recently, McEnaney et al have synthesized a class of 
antibody mimics that is composed of targeting and effector moieties, which has 
approximately 5% of the molecular weight of an antibody, demonstrating that the 
antibody analogy can selectively elicit an immune response for cellular phagocytosis 
through bivalent interactions.58 This may imply a new direction in drug discovery 
through the creation of miniaturized antibody mimics with small molecules.59  
    We are interested first in mimicking the antibody’s structure to understand effects of 
molecular architecture on functions of a molecule. The antibody is generally viewed as a 
Y-shaped molecule, which is composed of two Fab (fragment of antigen-binding) 
moieties connected to the Fc (fragment crystallizable) subunit through flexible linkers so 
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it can interact with its antigens bivalently. It is known that a bivalent interaction increases 
the affinity (i.e. avidity) and residence time of a drug molecule to its target.60 These two 
parameters are paramount for the development of effective therapeutic agents.61  
 A Y-shaped three-arm linker has been designed in order to build an antibody mimic. 
Such a scaffold would allow us to functionalize its two arms each with an affinity 
molecule to form a homo or hetero bivalent ligand, and leave the third arm for attaching a 
ligand that binds to a receptor on immune cells or a fluorescent dye for monitoring the 
bivalent interactions. The Y-shaped structure may have a more favourable geometry for a 
bivalent ligand binding to two separated binding sites of a receptor than a linear linker. 
To demonstrate the effectiveness of an antibody mimic for bivalent binding, the biotin-
streptavidin pair has been chosen as a model for the proof of principle study. The reason 
for choosing this pair as a model system is the fact that biotin-streptavidin pair is an 
example of one of strongest ligand-receptor interaction and the system has been well 
studied over the past decades. 
Biotin-streptavidin interaction 
 
    Streptavidin is homotetrameric protein isolated from Streptomyces avidini.62 Each 
monomer consists of eight antiparallel beta strands which in turn fold to form a beta 
barrel structure. Biotin is bound to the open end of the beta barrel structure. The affinity 
of this bonding is exceptionally high (dissociation constant 10-15 M).63 This high biotin- 
binding affinity of streptavidin arises from the following reasons. 
a) Biotin fits really well into the streptavidin pocket due to its high shape 
complementarity. 
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b) Hydrogen bonding involving Asp23, Tyr43, Ser27, Asn49, Ser88, 
Thr90 and Asp128 residues of streptavidin build up a strong network 
of interaction with biotin. 
c) Streptavidin has lots of aromatic contacts which help to make a 
hydrophobic network with biotin molecule. 
 
 
 
 
 
 
 
 
 
 
 
  (A)   (B) 
Figure 20. A) Biotin-streptavidin interaction through hydrogen bonding. B) molecular 
model structure showing tryptophan interaction with biotin.63 
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2.2. Results and discussion 
 
2.2.1 Design of three arm bisbiotin 
    Thermodynamically, if two ligands of a bivalent molecule are unstrained and 
independent, the change of enthalpy in the bivalent association (∆HBi) is twice as much as 
that in the monovalent binding (∆Hmono).64 
 
Figure 21. (A) A view of the crystal structure of a biotin-streptavidin complex from 
Protein Data Bank (PDB ID: 3RY2); (B) Distances between biotins in the complex, 
determined by measuring the distance between the ureido oxygen atoms, and between 
oxygen atoms of the carboxylates in the crystal structure; (C) Chemical structure of a 
three arm bisbiotin ligand; (D) A DFT model of three arm bisbiotin, calculated by 
B3LYP in combination with 6-31G* basis sets in a vacuum using software Spartan’14. 
  (A)   (B) 
  (C)   (D) 
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We have implemented these thermodynamic principles in our design of the three arm 
linker, managing (a) to make a bivalent structure with sufficient flexibility so that its two 
ligands can bind to the receptor in much the same way as they are in the free state; (b) to 
maximize the rigidity of the structure to reduce the possible loss in conformational 
entropy upon binding; (c) to avoid non-specific interactions of the scaffold with the 
receptor and other non-targeting molecules, which are often driven by cooperative 
hydrogen bonding, desolvation, or counter-ion release. For example, when DNA is used 
as a linker, it can interact with proteins through electrostatic attraction, which may 
become an entropically favorable process due to the release of the counterions,65,66 
resulting in strong nonspecific binding. 
    In the present study, we chose the biotin-streptavidin interaction as a model because it 
is one of the most studied system, which has a well-defined crystal structure (Resolution: 
0.95 Å).67 The streptavidin is a tetrameric molecule, each subunit bearing a biotin binding 
site.62 From the projection of the X-ray structure shown in Figure 21-A, three bound 
biotin molecules can be clearly seen in the streptavidin-biotin complex, indicating that 
these binding sites are accessible simultaneously by a bi- or tri-valent ligand. This has 
been demonstrated by Taylor et al using trisbiotinylated oligonucleotides with the length 
of > 20 nucleotides to occupy three of streptavidin’s four biotin-binding sites.68 As shown 
in Figure 21-B, those biotin molecules in the complex are separated by a range from 19 to 
35 Å. Based on these data, we designed the three arm bisbiotin molecule, shown in 
Figure 21-C. It is composed of a rigid core of 3,5-bis(phenylethynyl)aniline with a width 
of ~17 Å, which is surrounded with flexible oligo[ethylene glycol] (OEG) linkers. In 
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turn, two biotin molecules are respectively attached to those OEG linkers situated at the 
para positions of the phenyl ring 1 and 3, and the third function (azide in the figure) to the 
aniline fragment also through a flexible OEG linker. The DFT (Density Functional 
Theory) modeling shows that the structure can display as a Y shape with its two biotins 
separated by a distance of about 34 Å (Figure 21-D), which matches the distance between 
biotin 1 and biotin 2 in the crystal structure (see Figure 21-B). We designate the two 
branches connecting to biotins as Arm 1 and Arm 2, and the third one as the Stem (see 
Figure 21-D). The short OEG (6 ethylene glycol units) in the structure should allow the 
biotin moiety to have sufficient freedom for the binding and also improves solubility of 
the three arm bisbiotin in water.  
    We believe that the span between the two biotins in the Y-shape structure should be 
wide enough for them to bind the streptavidin simultaneously. In the present study, we 
used the stem (Figure 21-D) to immobilize the three arm bisbiotin on an SPR chip for 
studying the kinetics of the bivalent interaction. Similarly, we attached the three arm 
bisbiotin molecule to an atomic force microscopy (AFM) tip for studying the bivalent 
interactions at a single molecule level. 
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2.2.2 Synthesis of three arm bisbiotin 
    We have developed a synthetic route to preparing three arm bisbiotin (Scheme 2). 
Under the Sonogashira cross-coupling conditions,69,70 3,5-diethynylaniline (1)71 reacted 
with p-iodobenzyloxy-(OEG)6-NHBoc (2, see experimental section for its synthesis), 
producing compound 3 in a 75% yield. In the presence of pyridine, the arylamine of 
compound 3 reacted with α-OEGylated acetyl chloride S7a and S7b (see experimental 
section for their synthesis) respectively, generating 4a (59% yield) and 4b (69% yield), 
which were subsequently treated with trifluoroacetic acid to remove the Boc protecting 
groups, resulting in the scaffold molecules 5a (69% yield) and 5b (70% yield). The 
desired three arm bisbiotin ligands 6a and 6b were produced via 5a and 5b reacting with 
biotin N-hydroxysuccinimide ester in a yield of ~ 62% and 67%, respectively. The 
molecules 6a and 6b differ in the length of their stems. We studied their interactions with 
streptavidin by AFM and SPR, respectively.  
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To study the interactions of three arm bisbiotin with streptavidin by Surface Plasmon 
Resonance (SPR), a ω-thiolated alkyl chain was added to the azido end of 6a (Scheme 3). 
We synthesized a triphenyl phosphane 11-(acetylthio)undecanoate reagent 7 (see 
experimental section) to react with 6a, furnishing compound 8 containing an acetylated 
thiol via a traceless Staudinger ligation.72 In addition, both monobiotin 9 (purchased from 
Quanta Biodesign) and 10 (see experimental section for its synthesis) were used as 
Scheme 1. Synthesis of three arm bisbiotin ligands 
Reagents and conditions: (i) Pd(PPh3)2Cl2, CuI, THF : Et3N = 1:1, rt, 5 h; (ii) S7a or 
S7b, pyridine in dichloromethane, rt, 12 h; (iii) trifluoroacetic acid, rt, 10 min; (iv) 
biotin N-hydroxysuccinimide ester, triethylamine, DMF, rt, 3 h 
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controls, and compound 11 (see experimental section for its synthesis) as a spacer for 
formation of mixed monolayers (Figure 21). 
 
Figure 22. Structures of monobiotin ligands and spacer used in formation of mixed 
monolayers (Ac = acetyl) 
  
Scheme 2. Thiolation of three arm bisbiotin by Staudinger ligation 
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2.2.3 Kinetics of three arm bisbiotin binding to streptavidin 
    In turn, we have studied the kinetics of three arm bisbiotin interacting with streptavidin 
by means of SPR. For comparison, we constructed two mixed self-assembled monolayers 
  (A) 
  (B) 
Figure 23. Schematic representation of SPR experiment performed on A) SAM-mb, B) 
SAM-bb. On both cases, first streptavidin was run over the mixed monolayers to from 
the biotin-streptavidin complex, followed by flowing excess biotin solution over the 
complex to check its stability.  
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on gold substrates (Figure 23): one was composed of the monobiotin 10 with spacer 11 
(SAM-mb, illustrated in Figure 23-A), and the other one composed of three arm bisbiotin 
8 also with spacer 11 (SAM-bb, illustrated in Figure 23-B). It should be noted that we 
made these monolayer components with a mercaptoundecyl (11 carbons) chain at their 
Figure 24. (A) Schematic illustration of a mixed monolayer composed of the 
monobiotinylated ligand and a molecular spacer; (B) Schematic illustration of a mixed 
monolayer composed of three arm bisbiotin and a molecular spacer; (C) SPR sensorgram 
of adsorption and desorption of streptavidin on monobiotinyl formed monolayer; (D) 
SPR sensorgram of adsorption and desorption of streptavidin on the bisbiotinyl formed 
monolayer. Red and green dot lines: fitting curves. 
  (A)   (C) 
  (B)   (D) 
  (2) 
  (1) 
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ends. Presumably, the odd number of CH2 units in these molecules would give the 
monolayer better orientation and higher packing density in comparison to an even 
number of CH2 units, due to the odd-even effect.
73 The monolayers were prepared in 
ethanolic solution, and characterized with contact angle goniometry, ellipsometry, and 
FTIR (see experimental section). The ratio of biotin to spacer in the solution was adjusted 
to 1:9, which gave the highest SPR signals on the monolayers than other ratios. First, we 
examined non-specific absorption on these two monolayers by flowing a solution of 
streptavidin blocked by native biotins, finding that neither of the two monolayers had 
measurable non-specific adsorption (data not shown). Then, we measured SPR 
sensorgrams of streptavidin on these two monolayers. Figure 24-C shows a sensorgram 
generated on the SAM-mb by flowing a streptavidin solution, followed by a buffer 
solution, a biotin solution, and then the buffer solution again. Figure 24-D shows the 
sensorgram generated on the SAM-bb in the same fashion. By comparing between these 
two sensorgrams, one can notice that the SPR response generated from the streptavidin 
absorption was about two-thirds stronger on the SAM-mb than on the SAM-bb. This 
could be because less three arm bisbiotin was incorporated into the mixed monolayer in 
comparison to the monobiotin under the same reaction conditions and/or the three arm 
bisbiotin was less reactive to the gold substrate than the monobiotin or the spacer. From 
the sensorgrams, we were able to extract the kinetic data. First, we determined the 
association rate constants of the monobiotin at 30 µL/min flow rate by fitting association 
curve to the Langmuir model, finding that the association rate constant kon 4.9 x 10
4 M-1s
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1. kon for streptavidin binding to monobiotin is almost as same as to the value for binding 
to the three arm bisbiotin. 
  
 
 
 
 
 
Since, desorption of streptavidin from the biotinylated surface was unobservable in a pure 
buffer in an SPR time frame, we utilized a competition method to accelerate the 
dissociation process by flowing a 3 mM biotin solution through the monolayer. More 
than 50% of streptavidin was desorbed from the SAM-mb in 30 minutes. The dissociation 
curve was fitted into a bi-exponential decay function (green dot line in Figure 24-C),74 
resulting in two dissociation rate constants koff
1 and koff
2 (Table 1). We employ a model 
proposed by Pérez-Luna et al (see insert 1 and 2 in Figure 24-C) to explain the result.75 
On the SAM-mb, streptavidin formed both monovalent and bivalent complexes with the 
monobiotin ligand. The monovalent complex would desorb from the monolayer faster 
than the bivalent one. Accordingly, we assign the koff
1 to streptavidin dissociating from 
the monovalent complex and koff
2 from the bivalent complex. However, we should point 
out that the streptavidin formed an intermolecular bivalent complex with the mono biotin 
ligand on the SAM-mb. Strikingly, there was no desorption of streptavidin on the SAM-
bb, even after flowing a biotin solution (3 mM). We believe that the streptavidin formed 
Table 1. Kinetic parameters of adsorption and desorption of 
streptavidin on biotinylated monolayers 
 Flow rate 
(µL/min) 
SAM-mb SAM-bb 
koff
1 (s-1) 30 9.1 ± 1.5 x 10-3 ND 
koff
2 (s-1) 7.1 ± 1.2 x 10-4 ND 
 
ND: not able to determine. Green dot line: fitting curve for 
dissociation rate. Each rate constant is an average of three 
independent experiments. 
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an extremely stable intramolecular bivalent complex with three arm bisbiotin on the 
SAM-bb (see insert in Figure 24-D) because the three arm bisbiotin fits well with the 
streptavidin structure, resulting in a synergetic interaction. 
    There is always chance for the surface bound biotin ligand to get rebound to 
streptavidin pocket in the flow cell. But, for this experiment we were using 3mM of free 
biotin which was very high concentration compared to the biotin concentration on the 
surface. Therefore, it was highly unlikely that surface bound three arm bis biotin will be 
able to rebind to streptavidin after its detachment from one pocket. Also, if we could 
predict time scale for three arm bis biotin streptavidin from monobiotin dissociation time 
scale we would come up with fairly large time needed for streptavidin biotin complex 
dissociation from bis biotin. To check this part, dissociation experiment was performed 
for couple of hours without any dissociation. Also, excess biotin was run for three times 
over the streptavidin-biotin complex to see if there was any dissociation due to multiple 
run. But, no dissociation was observed for three arm bis biotin streptavidin complex. This 
reinforces the fact that three arm bis biotin form far more stable complex than linear 
biotin. 
2.2.4 AFM measurement of forces to break the three arm bisbiotin-streptavidin 
complex 
    Gomez-Casado et al has demonstrated that the AFM technique is an effective tool to 
study the interactions of multivalent adamantane ligands with cyclodextrins immobilized 
on a surface.76 Accordingly, we have attempted to measure the force needed to break the 
“indissociable” three arm bisbiotin-streptavidin complex using AFM at a single molecule 
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level. As illustrated in Figure 25-A, three arm bisbiotin was attached to AFM tips through 
a spontaneous reaction of azido function with a cyclooctyne functionalized AFM tip, a 
process we previously developed for recognition imaging.77 The streptavidin molecules 
were immobilized on a mica substrate functionalized with 3-aminopropyltriethoxysilane 
(APTES)/glutaraldehyde—a process developed in our laboratory for immobilization of 
proteins (Figure 25-B).78 To have a better insight into the bivalent interactions, we 
measured AFM force spectra of both three arm bisbiotin 6b and the control molecule 
monobiotin 9 interacting with streptavidin under the same conditions. The AFM force 
measurements were carried out in a phosphate buffer, pH 7.4, and ~ 1100 force-distance 
curves collected for each measurement. As shown in Figure 25-C, there are two main 
rupture events occurring in the force-distance curves, one of which is located within a 
range of distance from 2 to 7 nm and the other around 12-15 nm. We confirmed that the 
short distance rupture was due to non-specific interactions of the AFM tip with the 
surface by blocking. In a typical blocking experiment (performed after collecting force-
distance curves), we injected a streptavidin solution into the flow cell, which blocked 
those 
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biotin molecules on the tip from interacting with the streptavidin on the surface, and then 
collected another set of force-distance curves. We found that the rupture around the 
distance of 2-7 nm remained and those around the 12-15 nm disappeared (data not 
shown). Thus, we assign the ruptures in the range of 12-15 nm, which is close to the 
contour length of the linker (~11 nm estimated from the computer modeling), as the 
biotin unbinding from streptavidin. We also found that the ruptures of both monobiotin 
and three arm bisbiotin from streptavidin appeared as a single step event. On average, 
about 31% of the force-distance curves generated with a monobiotin-functionalized tip 
and 27% of those generated with a three arm bisbiotin-functionalized tip contained the 
specific ruptures, from which we determined the unbinding forces. Figure 25-D shows 
Figure 25. (A) Process of functionalizing AFM tips with a bisbiotin ligand, and (B) 
immobilizing streptavidin to a mica substrate; (C) A representative unbinding force-
distance curve of i: monobiotin 9, and ii: three arm bisbiotin 6b withdrawing from the 
streptavidin coated mica surface with a loading rate of 1.62 x 104 pN/s; (D) Force 
histogram of i: monobiotin 9 and ii: three arm bisbiotin 6b unbinding from streptavidin 
with their Gaussian fitting curves 
  (A) 
  (B) 
  (C)   (D) 
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the histogram distribution of the unbinding forces, which was analysed by first smoothing 
with the Savitzky-Golay method79 and then fitting with a Gaussian distribution. As a 
result, we obtained a mean value of 73.8±0.4 pN for unbinding of the monobiotin at the 
loading rate of 1.62 x 104 pN/s. This value is close to the most probable force (MPF) of 
one biotin unbinding from the streptavidin.80 In contrast, the histogram of the three arm 
bisbiotin was well fit to two Gaussians (Figure 25-D-ii). The first peak had a mean value 
of 73.6±1.7 pN. Therefore, we assign this peak to a monovalent unbinding of the three 
arm bisbiotin from streptavidin. Although this peak has a much wider force distribution 
than the monobiotin, it has the same mean value as the monobiotin. The discrepancy 
between the widths of the distributions may reflect the difference in structure between the 
three arm bisbiotin and the monobiotin. Notably, the second peak is situated at a mean 
value of 172.3±1.4 pN, which is twice as large as the rupture force of unbinding one 
biotin from the streptavidin. The second peak is well separated from the first one. This 
result indicates that the three arm bisbiotin did bind to streptavidin cooperatively without 
causing any significant strains. 
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2.3. Experimental procedures 
2.3.1 General information 
    All chemicals were purchased from commercial suppliers (Sigma-Aldrich, Fluka, 
Santa Cruz Biotechnology, Alfa Aesar). Anhydrous organic solvents were Sure/SealTM 
from Aldrich. Streptavidin and Dulbecco’s phosphate buffered saline solution (PBS, pH 
7.4) were purchased form Sigma-Aldrich., Azido-dPEG®23-biotin was purchased from 
Quanta Biodesign. All the synthetic reactions were carried out under nitrogen 
atmosphere. Thin layer chromatography (TLC) was used to monitor progress of organic 
reactions. An automated flash chromatography system (CombiFlash Rf, Teledyne Isco, 
Inc.) was used to separate the organic compounds with silica gel columns. FTIR data 
were collected using Thermo Scientific Nicolet™ 6700 FT-IR spectrometer. The HPLC 
purification was carried out in Agilent 1100 series equipped with a UV detector and a 
fraction collector. All the proton NMR (1H) spectra were recorded on a Varian 400 MHz 
instrument. 1H chemical shifts were referenced relative to the residual solvent peak (such 
as CDCl3: δH = 7.26 ppm). MALDI-TOF analysis was performed on Voyager-DE STR 
instrument. We used water from Millipore’s Milli-Q water purification system with a real 
time monitor of total of carbon (TOC) connected to a BioPak Polisher to remove 
biological contaminates. TOC level was strictly maintained below 5 ppb. 
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2.3.2 Synthesis 
Special note on nomenclature:  
    To avoid excessive use of a long series of numbers, the mathematical shorthand for 
expressing arithmetic progressions is used to denote the positions of oxygen atoms in the 
elongated PEG chains, as proposed by Hill and coworkers.81 
Synthesis of 1-(tert-butoxycarbonylamino)-17-p-iodobenzyloxy-3n15
3
 
pentaoxaheptadecane (2) 
The compound was synthesized following a route as described in Scheme 3.  
 
Scheme 3. Synthesis of compound 2 
  
  (S1) 
  (S2) 
  (S3) 
  (2) 
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1-Azido-17-p-iodobenzyloxy-3n15
3
-pentaoxaheptadecane (S2) Potassium tert-butoxide 
(1.26 g, 11.27 mmol) was added to a solution of 4-iodobenzyl alcohol (2.23 g, 9.5 mmol) 
in anhydrous THF (25 mL) followed by addition of S182 (4.0 g, 8.6 mmol) and the 
mixture was stirred at room temperature for 5 h, concentrated by rotary evaporation. The 
residue was purified by flash chromatography using a gradient of methanol (0-2.5% over 
4 h) in dichloromethane to give S2 as colorless oil (3.17 g, 70%). 1H NMR (400 MHz, 
CDCl3): δ 3.37 (t, 2H, J = 5.2 Hz), 3.58-3.68 (m, 22H), 4.50 (s, 2H ), 7.10 (d, 2H, J = 8 
Hz), 7.66 (d, 2 H, J = 8 Hz). 13C NMR (100 MHz, CDCl3): δ 40.3, 69.5, 70.0, 70.5-70.6, 
72.4, 129.5, 129.8, 137.4, 138.0. HRMS (APCI) (M+H): found m/z 524.1253, calcd for 
C19H30+1IN3O6 524.1254. 
1-Amino-17-p-iodobenzyloxy-3n15
3
-pentaoxaheptadecane (S3) To a solution of S2 (3 
g, 5.7 mmol) in anhydrous THF (20 mL), triphenylphosphine (2.25 g, 8.6 mmol) was 
added and stirred at room temperature for 12 h. Water (1 mL) was added to the mixture, 
which was stirring for another 4 h, concentrated by rotary evaporation. The crude product 
was purified by flash chromatography using a gradient of methanol (0-20% over 4 h) in 
dichloromethane to give S3 as colorless oil (2 g, 70%). 1H NMR (400 MHz, CDCl3): δ 
2.12 (s, 2H), 2.87 (t, 2H, J = 5 Hz), 3.37 (t, 2H, J = 5.2 Hz), 3.58-3.68 (m,  20H), 4.50 (s, 
2H ), 7.10 (d, 2H, J = 8 Hz), 7.66 (d, 2H , J = 8 Hz); 13C NMR (100MHz, CDCl3): δ 40.4, 
69.5, 70.1, 70.5-70.6, 72.4, 129.5, 129.8, 137.4, 138.0. HRMS (APCI) (M+H): found m/z 
498.1331, calcd for C19H32+1INO6 498.1335. 
1-(tert-butoxycarbonylamino)-17-p-iodobenzyloxy-3n15
3
-pentaoxaheptadecane (2) To 
a solution of S3 (2.0 g, 4 mmol) in anhydrous THF (15 mL), di-tert-butyl dicarbonate 
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(2.52 mL, 11 mmol) was added followed by addition of diisopropylamine (0.67 mL, 4.8 
mmol). The solution was stirred at room temperature for 15 h, concentrated by rotary 
evaporation. The residue was purified by flash chromatography using a gradient of 
methanol (0-5% over 4 h) in dichloromethane to give 2 as colorless oil (2.1 g, 87%). 1H 
NMR (400 MHz, CDCl3): δ 1.44 (s, 9H), 3.28-3.32 (m, 2H), 3.48 (t, 2H, J = 5.2 Hz), 
3.49-3.68 (m, 20H), 4.50 (s, 2H ), 5.11 (s, 1H), 7.10 (d, 2H, J = 8 Hz), 7.66 (d, 2 H, J = 8 
Hz); 13C NMR (100 MHz, CDCl3): δ 28.4, 40.3, 68.9, 69.5, 70.1, 70.5-70.6, 72.4, 129.5, 
129.8, 137.4, 138.0, 155.9. HRMS (APCI) (M+H): found m/z 598.1863, calcd for 
C24H40+1INO8 598.1867. 
Synthesis of 20-azido-3n18
3
-hexaoxaicosan-1-oyl chloride (S7a)  
The compound was synthesized following a route as described in Scheme 4. 
Tert-butyl 20-azido-3n18
3
-hexaoxaicosan-1-oate (S5a) To a solution of compound S4a82 
(2 g, 6.5 mmol) in anhydrous THF (10 mL), potassium tert-butoxide (0.54 g, 7.8 mmol) 
Scheme 4. Synthesis of compound S6a 
  
  (S4a) 
  (S5a) 
  (S6a) 
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was added followed by addition of tert-butyl bromoacetate (0.65 mL, 8.8 mmol). The 
mixture was stirred at room temperature for 5 h, and concentrated by rotary evaporation. 
The residue was purified by flash chromatography using a gradient of methanol (0-3.3% 
over 4 h) in dichloromethane to give S5a as colorless oil (1.2 g, 52%). 1H NMR (400 
MHz, CDCl3): δ 1.43 (m, 9H), 3.36 (t, 2 H, J = 5.2 Hz), 3.53-3.68 (m, 22H), 3.90 (s, 2H 
). 13C NMR (100 MHz, CDCl3): δ 28.03, 50.6, 68.9, 69.5, 70.0, 70.5-70.6, 72.4, 164.5. 
HRMS (APCI) (M+H): found m/z 422.3463, calcd for C18H35+1N3O8 422.3465. 
20-azido-3n18
3
-hexaoxaicosan-1-oic acid (S6a) Compound S5a (1.0 g, 2.4 mmol) was 
dissolved in 10 mL of trifluoroacetic acid and stirred for 4 h at room temperature, and 
concentrated by rotary evaporation. The residue was purified by flash chromatography 
using a gradient of methanol (0-6% over 3 h) in dichloromethane to give S6a as colorless 
oil (0.62 g, 73%). 1H NMR (400 MHz, CDCl3): δ 3.37 (t, 2 H, J = 5.2 Hz), 3.53-3.69  (m, 
22H), 3.93 (s, 2H). 13C NMR (100 MHz, CDCl3): δ 50.6, 69.1, 69.5, 70.0, 70.5-70.6, 
72.4, 166.8. HRMS (APCI) (M+H): found m/z 366.2754, calcd for C14H27+1N3O8 
366.2759. 
Synthesis of 20-azido-3n18
3
-hexaoxaicosan-1-oyl chloride (S7a) S6a (0.5 g, 1.2 mmol) 
was dissolved in thionyl chloride (2 mL, 2.7 mmol), stirred for 6 h at room temperature, 
and concentrated by rotary evaporation to furnish S7a as yellowish oil. 
56-azido-3n54
3
-octadecaoxahexapentacontan-1-oyl chloride (S7b) 
The compound was synthesized following a route as described in Scheme 6.  
53-azido-3n51
3
-heptadecaoxatripentacontan-1-ol (S4b)  
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The starting material S3b was synthesized following a procedure we previously 
reported.82  
To a solution of hexaethylene glycol (6.72 g, 23.8 mmol) in anhydrous THF (40 mL), 
Sodium hydride (0.74g, 30.8 mmol) was added and stirred at 0 °C for 1 h. Compound 
S3b (3.5 g, 7.5 mmol) in anhydrous THF (20 mL) was added to the mixture and allowed 
to warm to room temperature, stirred for another 15 h. Methanol (5 mL) was added 
dropwise to stop the reaction. The mixture was concentrated by rotary evaporation, 
purified in a silica gel column by flash chromatography using a gradient of methanol (0-
3.5% over 4 h) in dichloromethane. Compound S4b was obtained as a colorless liquid 
(2.9 g, 72%). 1H NMR (400 MHz, CDCl3): δ 2.69 (s, 1 H, broad), 3.36 (t, 2 H, J = 5.2 
Scheme 5. Synthesis of compound S6b 
  
  (S3b) 
  (S4b) 
  (S5b) 
  (S6b) 
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Hz), 3.53- 3.68 (m, 70 H). 13C NMR (100 MHz, CDCl3): δ 69.5, 70.1, 70.5-70.6, 72.4. 
HRMS (APCI) (M+H): found m/z 836.5330, calcd for C36H73+1N3O18 836.5332. 
Tert-butyl 56-azido-3n54
3
-octadecaoxahexapentacontan-1-oate (S5b) To a solution of 
compound S4b (2 g, 2.3 mmol) in anhydrous THF (10 mL), potassium tert-butoxide 
(0.34 g, 3.1 mmol) was added followed by addition of tert-butyl bromoacetate (0.45 mL, 
3.1 mmol). The mixture was stirred at room temperature for 5 h, and concentrated by 
rotary evaporation. The residue was purified by flash chromatography using a gradient of 
methanol (0-3.3% over 4 h) in dichloromethane to give S5b as colorless oil (1.3 g, 57%). 
1H NMR (400 MHz, CDCl3): δ 1.43 (m, 9H), 3.36 (t, 2 H, J = 5.2 Hz), 3.54-3.68  (m, 
70H), 3.91 (s, 2H). 13C NMR (100 MHz, CDCl3): δ 28.4, 50.6, 69.0, 69.5, 70.0, 70.5-
70.6, 72.4, 164.5. HRMS (APCI) (M+H): found m/z 950.6191, calcd for C42H83+1N3O20 
950.6192. 
56-Azido-3n54
3
-octadecaoxahexapentacontan-1-oic acid (S6b) Compound S5b (1.0 g, 
1 mmol) was dissolved in 10 mL of trifluoroacetic acid and stirred for 4 h at room 
temperature, and concentrated by rotary evaporation. The residue was purified by flash 
chromatography using a gradient of methanol (0-6% over 3 h) in dichloromethane to give 
S6b as colorless oil (0.65 g, 69%). 1H NMR (400 MHz, CDCl3): δ 3.37 (t, 2 H, J = 5.2 
Hz), 3.54-3.69  (m, 70H), 3.92 (s, 2H). 13C NMR (100 MHz, CDCl3): δ 50.6, 68.9, 69.5, 
70.0, 70.5-70.6, 72.4, 166.7. HRMS (APCI) (M+H): found m/z 894.5636, calcd for 
C38H75+1N3O20 894.5637 
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56-azido-3n54
3
-octadecaoxahexapentacontan-1-oyl chloride (S7b) S6b (0.5 g, 0.55 
mmol) was dissolved in thionyl chloride (2 mL, 2.7 mmol), stirred for 6 h at room 
temperature, concentrated by rotary evaporation to furnish S7b as yellowish oil. 
3,5-Bis{4-[19-tert-butoxycarbonylamino-(3n18
3
-1) 
hexaoxanonadecyl]phenylethynyl}aniline (3)  
To a solution of compound 2 (2.6 g, 4.4 mmol) in THF (20 mL), 3,5-diethynylaniline 171 
(0.3 g, 2.1 mmol), bis(triphenylphosphine)palladium(II)dichloride (0.074 g, 0.1 mmol) 
and copper(I) iodide (0.040 g, 0.2 mmol) were added. The mixture was stirred at room 
temperature for 5 h, filtered to remove the precipitate, concentrated by rotary 
Scheme 6. Synthesis of compound 3. 
  
  (1) 
  (3) 
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evaporation. The residue was purified by flash column chromatography on silica gel 
using a gradient of methanol (0-2.8% over 4 h) in dichloromethane as an eluent to give 3 
as a colorless oil (1.72 g, 75%). 1H NMR (400 MHz, CDCl3): δ 1.43 (s, 18H), 3.27-3.32 
(m, 4H), 3.52 (t, 4H, J = 5.2 Hz), 3.58-3.69 (m, 44 H), 4.56 (s, 4H), 5.13 (s, 2H), 6.81 (s, 
2H), 7.10 (s, 1H), 7.32 (d, 4H, J = 8 Hz), 7.47 (d, 4H, J = 8 Hz); 13C NMR (100 MHz, 
CDCl3): δ 28.3, 40.3, 69.5, 70.1, 70.3-70.6, 72.7, 88.9, 90.0, 117.7, 122.2, 124.0, 124.9, 
127.4, 131.5, 138.6, 146.5, 155.9; HRMS (APCI) (M+H): found m/z 1080.6002, calcd 
for C58H85+1N3O16 1080.6001. 
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N-(3,5-Bis{4-[19-tert-butoxycarbonylamino-(3n18
3
-1)-
hexaoxanonadecyl]phenylethynyl}aniline)-20-azido-3n18
3
-icosan-1-amide (4a) 
Compound S7a dissolved in anhydrous dichloromethane (1 mL) was added to a solution 
of compound 3 (1.4 g, 1.27 mmol) in anhydrous dichloromethane (10 mL) and pyridine 
(98 µL, 1.2 mmol). The solution was stirred for 12 h at room temperature, concentrated 
by rotary evaporation. The residue was purified by flash column chromatography on 
silica gel using a gradient of methanol (0-4% over 4 h) in dichloromethane as an eluent to 
give 4a as a colorless oil (1.1 g, 59%). 1H NMR (400 MHz, CDCl3): δ 1.43 (s, 18H), 
3.21-3.25 (m, 4H), 3.34 (t, 6H, J = 5.2 Hz), 3.51-3.78 (m, 62 H), 4.13 (s, 2H), 4.56 (s, 
4H), 5.13 (s, 2H), 6.81 (s, 2H), 7.12 (s, 1H), 7.33 (d, 4H, J = 8 Hz), 7.47 (d, 4H, J = 8 
  (S6a) 
  (S7a) 
  (3) 
  (4a) 
Scheme 7. Synthesis of compound 4a 
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Hz), 8.85 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 28.3, 40.3, 50.6, 69.4, 69.7, 69.9, 70.0, 
70.4-70.6, 72.7, 88.9, 90.0, 117.7, 122.3, 124.1, 124.9, 127.4, 131.6, 138.6, 146.5, 155.9, 
168.8. MALDI-MS (M+H): found m/z 1427.65, calcd for C72H110+1N6O23 1427.67. 
N-(3,5-Bis{4-[19-amino-(3n18
3
-1)-hexaoxanonadecylphenyl]ethynyl}aniline)-20-
Azido-3n18
3
-icosan-1-amide (5a) 
 Compound 4a (0.50 g, 0.35 mmol) was dissolved in a solution of TFA (0.3 mL, 3.3 
mmol) and anhydrous dichloromethane (0.2 ml). The solution was stirred for 10 minutes 
at room temperature, and concentrated by rotary evaporation. The residue was purified by 
flash column chromatography using a gradient of methanol (0-13% over 4 h) in 
dichloromethane as an eluent to give 5a as colorless oil (0.30 g, 69%). 1H NMR (400 
Scheme 8. Synthesis of compound 5a 
  
  (4a) 
  (5a) 
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MHz, CDCl3): δ 2.5 (s, 4H), 3.20-3.25 (m, 4H), 3.34 (t, 6H, J = 5.2 Hz), 3.50-3.77 (m, 62 
H), 4.13 (s, 2H), 4.56 (s, 4H), 6.80 (s, 2H), 7.11 (s, 1H), 7.32 (d, 4H, J = 8 Hz), 7.47 (d, 
4H, J = 8 Hz), 8.89 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 40.3, 50.6, 69.4, 69.7, 69.9, 
70.0, 70.4-70.6, 72.7, 88.9, 90.0, 117.7, 122.3, 124.1, 124.9, 127.4, 131.6, 138.6, 146.5, 
168.8; MALDI-MS (M+H): found m/z 1227.40, calcd for C62H94+1N6O19 1227.44. 
N-(3,5-Bis{4-[19-biotinylated-amino-(3n18
3
-1)-
hexaoxanonadecyl]phenylethynyl}aniline) )-20-Azido-3n18
3
-icosan-1-amide (6a)  
A solution of 5a (0.20 g, 0.16 mmol), NHS-Biotin (0.116 g, 0.34 mmol), and 
triethylamine (0.047 mL, 0.34 mmol) in anhydrous DMF (2 mL) was stirred at room 
temperature for 2.5 h, and concentrated by rotary evaporation. The residue was purified 
Scheme 9. Synthesis of compound 6a 
  
  (5a) 
  (6a) 
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by flash column chromatography on silica gel using a gradient of methanol (0-5% over 4 
h) in dichloromethane as an eluent to give 6a as a colorless oil (0.17 g, 62%). 1H NMR 
(400 MHz, CDCl3): δ 1.30-1.80 (m, 12H), 2.21 (t, 4H, J = 7.1 Hz), 2.72 (d, 2H, J = 12.5 
Hz), 2.86 (dd, 2H, J = 4.8 Hz, J = 12.5 Hz), 3.13-3.17 (m, 2H), 3.21-3.26 (m, 4H), 3.33 (t, 
6H, J = 5.2 Hz), 3.52-3.78 (m, 62 H), 4.13 (s, 2H), 4.31-4.35 (m, 2H), 4.49-4.53 (m, 2H), 
4.58 (s, 4H), 5.75 (s, 2H), 6.45 (s, 2H), 6.50 (s, 2H), 6.81 (s, 2H), 7.10 (s, 1H), 7.32 (d, 
4H, J = 8 Hz), 7.47 (d, 4H, J = 8 Hz), 8.91 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 25.5, 
28.0, 28.1, 35.8, 39.1, 40.3, 50.6, 55.5, 60.1, 61.7, 69.3, 69.7, 69.9, 70.0, 70.4-70.6, 72.7, 
88.9, 90.0, 117.7, 122.3, 124.1, 124.8, 127.4, 131.6, 138.6, 146.5, 163.9, 168.7, 173.5; 
MALDI-MS (M+H): found m/z 1679.76, calcd for C82H122+1N10O23S2 1679.81. 
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N-(3,5-Bis{4-[19-tert-butoxycarbonylamino-(3n18
3
-1)-
hexaoxanonadecyl]phenylethynyl}aniline)-56-azido-3n54
3
-
octadecaoxahexapentacontan-1-amide (4b)  
Compound S7b (see S2 in Supporting Information for its synthesis) dissolved in 
anhydrous dichloromethane (0.5 mL) was added to a solution of compound 3 (0.66 g, 0.6 
mmol) in anhydrous dichloromethane (0.5 mL) and pyridine (98 µL, 1.2 mmol). The 
solution was stirred for 12 h at room temperature, and then concentrated by rotary 
evaporation. The residue was purified by flash column chromatography on silica gel 
using a gradient of methanol (0-4% over 4 h) in dichloromethane as an eluent to give 4b 
as a colorless oil (0.76 g, 69%). 1H NMR (400 MHz, CDCl3): δ 1.43 (s, 18H), 3.20-3.25 
Scheme 10. Synthesis of compound 4b 
  
  (4b) 
  (3) 
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(m, 4H), 3.34 (t, 6H, J = 5.2 Hz), 3.52-3.78 (m, 110 H), 4.13 (s, 2H), 4.56 (s, 4H), 5.13 (s, 
2H), 6.80 (s, 2H), 7.12 (s, 1H), 7.32 (d, 4H, J = 8 Hz), 7.47 (d, 4H, J = 8 Hz), 8.85 (s, 
1H); 13C NMR (100 MHz, CDCl3): δ 28.3, 40.3, 50.6, 69.4, 69.7, 69.9, 70.0, 70.3-70.6, 
72.7, 88.9, 90.0, 117.7, 122.3, 124.1, 124.9, 127.4, 131.6, 138.6, 146.5, 155.9, 168.9. 
MALDI-MS (M+H): found m/z 1957.36, calcd for C96H158+1N6O35 1957.31. 
N-(3,5-Bis{4-[19-amino-(3n18
3
-1)-hexaoxanonadecyl]phenylethynyl}aniline)-56-
Azido-3n54
3
-octadecaoxahexapentacontan-1-amide (5b)  
Compound 4b (0.7 g, 0.35 mmol) was dissolved in a solution of TFA (0.3 ml) and 
anhydrous dichloromethane (0.2 ml). The solution was stirred for 10 minutes at room 
temperature, and then concentrated by rotary evaporation. The residue was purified by 
flash column chromatography using a gradient of methanol (0-13% over 4 h) in 
dichloromethane as an eluent to give 5b as colorless oil (0.44 g, 70%). 1H NMR (400 
Scheme 11. Synthesis of compound 5b 
  
  (4b) 
  (5b) 
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MHz, CDCl3): δ 2.5 (s, 4H), 3.20-3.25 (m, 4H), 3.34 (t, 6H, J = 5.2 Hz), 3.50-3.77 (m, 
110 H), 4.13 (s, 2H), 4.56 (s, 4H), 6.81 (s, 2H), 7.11 (s, 1H), 7.32 (d, 4H, J = 8 Hz), 7.47 
(d, 4H, J = 8 Hz), 8.89 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 40.3, 50.6, 69.4, 69.7, 
69.9, 70.0, 70.3-70.6, 72.7, 88.9, 90.0, 117.7, 122.3, 124.1, 124.9, 127.4, 131.6, 138.6, 
146.5, 168.9; MALDI-MS (M+H): found m/z 1757.16, calcd for C86H142+1N6O31 
1757.07. 
N-(3,5-Bis{4-[19-biotinylated-amino-(3n18
3
-1)-
hexaoxanonadecyl]phenylethynyl}aniline)-56-Azido-3n54
3
-
octadecaoxahexapentacontan-1-amide (6b)  
To a solution of 5b (0.2 g, 0.11 mmol), NHS-Biotin (0.116 g, 0.34 mmol), and 
triethylamine (0.047 mL, 0.34 mmol) in anhydrous DMF (2 mL) was stirred at room 
Scheme 12. Synthesis of compound 6b 
  
  (5b) 
  (6b) 
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temperature for 2.5 h, and concentrated by rotary evaporation. The residue was purified 
by flash column chromatography on silica gel using a gradient of methanol (0-5% over 4 
h) in dichloromethane as an eluent to give 6b as a colorless oil (0.17 g, 67%). 1H NMR 
(400 MHz, CDCl3): δ 1.30-1.80 (m, 12H), 2.21 (t, 4H, J = 7.1 Hz), 2.72 (d, 2H, J = 12.5 
Hz), 2.86 (dd, 2H, J = 4.8 Hz, J = 12.5 Hz), 3.13-3.17 (m, 2H), 3.21-3.26 (m, 4H), 3.33 (t, 
6H, J = 5.2 Hz), 3.52-3.78 (m, 110 H), 4.13 (s, 2H), 4.30-4.35 (m, 2H), 4.49-4.52 (m, 
2H), 4.58 (s, 4H), 5.75 (s, 2H), 6.45 (s, 2H), 6.50 (s, 2H), 6.81 (s, 2H), 7.09 (s, 1H), 7.32 
(d, 4H, J = 8 Hz), 7.47 (d, 4H, J = 8 Hz), 8.90 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 
25.5, 28.0, 28.1, 35.8, 39.1, 40.3, 50.6, 55.5, 60.1, 61.7, 69.3, 69.7, 69.9, 70.0, 70.3-70.6, 
72.7, 88.9, 90.0, 117.7, 122.3, 124.1, 124.8, 127.4, 131.6, 138.6, 146.5, 163.9, 168.8, 
173.4; MALDI-MS (M+H): found m/z 2209.52, calcd for C106H170+1N10O35S2 2209.66. 
Synthesis of triphenyl phosphane 11-(acetylthio)undecanoate (7) Compound 7 was 
synthesized following the route in scheme 13. 
S14 was synthesized following literature procedure.83 1H NMR (400 MHz, CDCl3): δ 
1.22-1.47 (m, 14H), 1.52-1.63 (m, 4H), 2.31 (s, 3H), 2.34 (t, 2H, J = 5.2 Hz), 2.84 (t, 2H, 
J = 7.6 Hz). 13C NMR (100 MHz, CDCl3): δ 26.4, 28.9, 29.2, 29.6, 29.8-29.9, 32.5, 34.2, 
39.5, 165.3, 195.0. HRMS (APCI) (M+H): found m/z 274.1346, calcd for C13H25+1O3S 
274.1355. 
  (S14)   (7) 
Scheme 13. Synthesis of compound 7 
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To a stirred solution of S14 (0.5 g, 1.8 mmol) in 5 mL anhydrous DMF, EDC (0.5 g, 2.5 
mmol) and catalytic amount of DMAP (0.010 g, 0.01 mmol) were added and stirred at 0 
°C for 30 minutes. To this solution, (2-Hydroxyphenyl)diphenylphosphine (0.52 g, 1.8 
mmol) in 5 mL anhydrous DMF was added and stirred overnight. Then the solvent was 
evaporated and the residue was purified by flash column chromatography on silica gel 
using a gradient of methanol (0 - 5% over 4 h) in dichloromethane as an eluent to give 
compound 7 (0.7 g, 63%). 1H NMR (400 MHz, CDCl3): δ  1.22-1.47 (m, 14H), 1.52-1.63 
(m, 4H), 2.31 (s, 3H), 2.34 (t, 2H, J = 7.6 Hz), 2.86 (t, 2H, J = 7.2 Hz), 6.76-6.84 (m, 
1H), 7.06-7.16 (m, 2H), 7.23-7.40 (m, 11H). 13C NMR (100 MHz, CDCl3): δ 26.4, 28.9, 
29.2, 29.6, 29.8-29.9, 32.5, 34.2, 39.5, 122.4, 126.3, 128.4, 128.7, 129.1, 130.2, 130.3, 
133.5, 133.8, 134.2, 135.6, 135.7, 164.3, 195.1. HRMS (APCI) (M+H): found m/z 
535.6918, calcd for C32H39+1O3PS 535.6915. 
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N-(3,5-Bis{4-[19-biotinylated-amino-(3n18
3
-1)-
hexaoxanonadecyl]phenylethynyl}aniline)-20-(11-acetylthioundecanamido)-3n18
3
-
hexaoxaicosan-1-amide (8) 
A solution of 7 (0.065 g, 0.13 mmol) and 6a (0.2 g, 0.1 mmol) in DMF (1.5 mL) and 
water (500 µL) was stirred at 100 °C for 1 h, and concentrated by rotary evaporation. The 
residue was separated by flash column chromatography on silica gel using a gradient of 
methanol (0-4.5% over 4h) in dichloromethane as an eluent to give 8 as a colorless oil 
(35 mg, 87 %). 1H NMR (400 MHz, CDCl3): δ 1.26-1.79 (m, 30H), 2.21 (t, 6H, J = 7.1 
Hz), 2.26 (s, 3H), 2.32 (t, 2H, J = 5.2 Hz), 2.72 (d, 2H, J = 12.5 Hz), 2.86 (dd, 2H, J = 4.8 
Hz, J = 12.5 Hz), 3.13-3.17 (m, 2H), 3.20-3.25 (m, 6H), 3.34 (t, 6H, J = 5.2 Hz), 3.52-
3.78 (m, 60 H), 4.13 (s, 2H), 4.30-4.35 (m, 2H), 4.49-4.52 (m, 2H), 4.58 (s, 4H), 5.76 (s, 
3H), 6.45 (s, 2H), 6.50 (s, 2H), 6.81 (s, 2H), 7.09 (s, 1H), 7.32 (d, 4H, J = 8 Hz), 7.47 (d, 
4H, J = 8 Hz), 8.91 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 25.5, 26.3, 28.0, 28.1, 28.9, 
Scheme 14. Synthesis of compound 8 
  
  (7)   (8) 
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29.2, 29.5, 29.8-29.9, 32.5, 35.8, 39.1, 40.3, 50.6, 55.5, 60.1, 61.7, 69.3, 69.7, 69.9, 70.0, 
70.3-70.6, 72.7, 88.9, 90.0, 117.7, 122.3, 124.1, 124.8, 127.4, 131.6, 138.6, 146.5, 163.9, 
168.8, 173.4, 195.1; MALDI-MS (M+H): found m/z 1909.87, calcd for C96H148+1N8O25S3 
1909.97. 
Synthesis of N-(biotinylatedamido)-18-(11-acetylthioundecano)-3n18
3
-
hexaoxaoctadecan-1-amide (10) The biotin functionalized linker 10 was synthesized as 
described in scheme 16. 
Compound S4a82 was synthesized as we reported earlier. Compound S4a (1 g, 3.3 mmol) 
and NaH (96 mg, 4 mmol) were dissolved in dry DMF and stirred for 30 min at 0 °C. The 
resulting solution was added drop wise to 1,11-dibromoundecane (0.93 g, 0.7 mL, 3 
mmol) in dry DMF and subsequently stirred for 12 h. The reaction was quenched with 
methanol and the solvent was evaporated in a rotavapor. The resulting oil was dissolved 
Scheme 15. Synthesis of compound 11 
  
  (S4a)   (S8)   (S9) 
  (7) 
  (S9) 
  (S10) 
  (S10) 
  (11) 
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in 100 mL dichloromethane, washed thrice with water, and dried over MgSO4. 
Subsequently, the solvent was evaporated and the residue was purified by column 
chromatography using 6% methanol inn dichloromethane over 4 h yielding 1.2 g of 
compound S8 (68%), as verified by NMR and mass spectrometry. 1H NMR (400 Hz, 
CDCl3): δ 1.19-1.24 (m, 14H), 1.4 (t, 2H, J = 6.8 Hz), 1.55 (q, 2H, J = 6.8 Hz), 1.83 (q, 
2H, J = 6.8 Hz), 3.37 (t, 2H, J = 5.2 Hz), 3.42 (t, 2H, J = 6.8 Hz), 3.55 (t, 2H, J = 5.2 Hz), 
3.59-3.68 (m, 20H). 13C NMR (100 MHz, CDCl3): δ characteristic peaks for PEG and PE 
were observed. HRMS (APCI) (M+H): found m/z 540.2581, calcd for C23H46+1BrN3O6 
540.2650. 
To a stirred solution of compound S8 (1.1 g, 2.2 mmol) in dry DMF, potassium 
thioacetate (0.28 g, 2.4 mmol) was added and the resulting mixture was stirred overnight 
at 40 °C. Then the solvent was evaporated and the residue was purified by column 
chromatography using 5% DCM in methanol to yield 0.9 g of compound S9 (82%). 1H 
NMR (400 MHz, CDCl3): δ 1.21-1.4 (m, 14H), 1.46-1.59 (m, 4H), 2.29 (s, 3H), 2.83 (t, 
2H, J = 7.2 Hz), 3.35 (t, 2H, J= 5.2 Hz), 3.41 (t, 2H, J = 6.8 Hz), 3.54 (t, 2H, J= 5.2 Hz), 
3.6-3.72 (m, 20H). 13C NMR (100 MHz, CDCl3): δ  characteristic peaks for PEG and PE 
were observed. Characteristic peak for carbonyl was observed at δ= 195.9. HRMS 
(APCI) (M+H): found m/z 536.3379, calcd for C25H49+1N3O7S 536.3371. 
To a stirred solution of D-biotin (0.50 g, 2 mmol) in 5 mL dry DMF, EDC (0.51 g, 2.7 
mmol) and catalytic amount of DMAP (10 mg) were added and stirred at 0 °C for 30 
minutes. To this solution (2-Hydroxyphenyl)diphenylphosphine (0.57 g, 2 mmol) in 5 mL 
dry DMF was added and stirred overnight. Then the solvent was evaporated and the 
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residue was purified using 5% methanol in DCM to yield compound S10 (0.61 g, 59%). 
1H NMR (400 MHz, CDCl3): δ 1.34 (quin, 2H, J = 7.6 Hz), 1.44-1.70 (m, 4H), 2.27 (t, 
2H, J = 7.6 Hz), 2.67 (d, 1H, J = 12.8 Hz), 2.74-2.87 (m, 1H), 3.0-3.10 (m, 1H), 4.18-
4.25 (m, 1H), 4.37-4.44 (m, 1H), 5.81 (s, 1H), 6.33 (s, 1H), 6.76-6.84 (m, 1H), 7.06-7.16 
(m, 2H), 7.23-7.40 (m, 11H). 13C NMR (100 MHz, CDCl3): δ  24.3, 28.2, 33.6, 40.5, 
55.5, 60.1, 61.9, 122.5, 126.1, 128.5, 128.6, 129.0, 129.9, 130.0, 130.2, 133.7, 133.8, 
134.0, 135.5, 135.5, 152.7, 152.8, 164.0, 171.5. HRMS (APCI) (M+H): found m/z 
505.1725, calcd for C28H29+1N2O3PS 505.1717. 
To a stirred solution of compound S10 (0.5 g, 1 mmol) in 5 mL DMF:water (10:1) was 
added solution of compound S9 (0.53 g, 1 mmol) in 5 mL DMF:water (10:1) and reaction 
mixture was stirred at 100 °C for 1 h. Then the solvent was evaporated and the resulting 
residue was purified using 10% methanol-DCM to give compound 8 (0.51 g, 74%). 1H 
NMR (400 MHz, CDCl3): δ  1.12-1.72 (m, 21H), 2.16 (t, 2H, J = 7.2 Hz), 2.25 (s, 3H), 
2.46 (d, 1H, J =12.8 Hz), 2.74-2.84 (m, 4H), 3.01-3.11 (m, 1H), 3.30-3.41 (m, 4H), 3.47-
3.53 (m, 4H), 3.53-3.63 (m, 20H), 4.21-4.26 (m, 1H), 4.4-4.47 (m, 1H), 5.9 (s, 1H, 
broad), 6.76 (s, 1H, broad), 6.88 (s, 1H, broad); 13C NMR (100 MHz, CDCl3): δ 
characteristic peaks for PEG and PE were observed. 3 carbonyl peaks were observed at δ 
= 164.2, 173.4, 195.97; HRMS (APCI) (M+H): found m/z 736.4217, calcd for 
C35H65+1N3O9S2 736.4242. 
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Synthesis of 18-(11-acetylthioundecano)-3n18
3
-hexaoxaoctadecan-1-ol (5) The control 
molecule 11 was synthesized as followed 17. 
Compound S11 (1 g, 2 mmol) and NaH (0.057 g, 2.4 mmol) were dissolved in dry DMF 
and stirred for 30 min at 0 °C. The resulting solution was added drop wise to 1,11-
dibromoundecane (0.57 g, 0.42 mL, 1.8 mmol) in dry DMF and subsequently stirred for 
12 h. The reaction was quenched with methanol and the solvent was evaporated. The 
resulting oil was dissolved in 250 mL dichloromethane, washed thrice with water, and 
dried over MgSO4. Subsequently, the solvent was evaporated and the residue was 
purified by column chromatography using 6% methanol inn dichloromethane over 4 h 
yielding 1.29 g of compound S12 (68%), as verified by NMR and mass spectrometry. 1H 
NMR (400 MHz, CDCl3): δ 1.21-1.46 (m, 14H), 1.55 (q, 2H, J = 6.8 Hz), 1.83 (q, 2H, J 
= 7.2 Hz), 3.22 (t, 2H, J = 5.2 Hz), 3.38 (t, 2H, J = 6.8 Hz), 3.42 (t, 2H, J = 6.8 Hz), 3.54 
(t, 2H, J = 5.2 Hz), 3.58-3.7 (m, 20H), 7.16-7.48 (m, 15H, aromatic). 13C NMR (100 
Scheme 16. Synthesis of compound 11 
  
  (S11)   (S12) 
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MHz, CDCl3): δ characteristic peaks for PEG and PE were observed. Peaks for aromatic 
carbons were at δ= 126.89, 127.73, 128.69, 144.11. HRMS (APCI) (M+H): found m/z 
756.3668, calcd for C42H61+1BrO7 757.3679. 
To a stirred solution of compound S12 (1 g, 1.3 mmol) in dry DMF, potassium 
thioacetate (0.162 g, 1.4 mmol) was added and the resulting mixture was stirred overnight 
at 40 °C. Then the solvent was evaporated and the residue was purified by column 
chromatography using 5% DCM in methanol to yield 0.8 g of compound S13 (81%). 1H 
NMR (400 MHz, CDCl3): δ 1.18-1.36 (m, 14H), 1.47-1.61 (m, 4H), 2.29 (s, 3H), 2.83 (t, 
2H, J = 7.2 Hz), 3.21 (t, 2H, J = 5.2 Hz), 3.41 (t, 2H, J = 6.8 Hz), 3.54 (t, 2H, J = 5.2 Hz), 
3.57- 3.72 (m, 20 H), 7.15-7.49 (m, 15H, aromatic); 13C NMR (100 MHz, CDCl3): δ 
characteristic peaks for PEG and PE were observed. Other peaks were δ= 126.88, 127.73, 
128.69, 144.10 (all aromatic) and 196.02 (carbonyl). HRMS (APCI) (M+H): found m/z 
753.4415, calcd for C44H64+1O8S 753.4402. 
A solution of 50% trifluoroacetic acid (1 mL) was added to a mixture of S13 (0.75g, 1.0 
mmol) in DCM (10 mL) at 0 °C, and stirred 1 h. The reaction was poured into saturated 
NaHCO3 and extracted with DCM. The combined organic layers were washed with brine 
and dried over Na2SO4. After filtration, the filtrate was evaporated in vacuo and purified 
by column chromatography on silica gel (elution; 10% MeOH in DCM). Production 
fractions were collected and evaporated in vacuo to give compound 11 (light yellow oil, 
0.39 g, 76%). %). 1H NMR (400 MHz, CDCl3): δ 1.14-1.38 (m, 14H), 1.45-1.59 (m, 4H), 
2.28 (s, 3H), 2.62 (broad, 1H), 2.82 (t, 2H, J = 7.2 Hz), 3.40 (t, 2H, J = 6.8 Hz), 3.49-3.66 
(m, 24 H); 13C NMR (100 MHz, CDCl3): δ characteristic peaks for PEG and PE were 
 69 
 
observed. Carbonyl peak was observed at δ= 196.05 (carbonyl). HRMS (APCI) (M+H): 
found m/z 511.3310, calcd for C25H50+1O8S 511.3305. 
2.3.3 Preparation and characterization of mixed monolayers  
    Both monolayer SAM-mb and SAM-bb was prepared by the following procedure. To a 
mixed solution of the monobiotinyl ligand 10 or three arm bisbiotin 8 (10 µM) and the 
spacer 11 (90 µM) in an absolute ethanol (3 mL) was pyrrolidine (30 µL, 0.36 mM) 
added in a Petri dish covered with a lid. After 15 min, thin layer chromatography (TLC) 
showed that the acetyl group was removed to free the thiol group. A gold chip was 
immersed in the solution for 24 h, followed by rinsing with absolute ethanol and drying 
with a nitrogen flow, and used immediately. The chip was characterized by contact angle 
goniometry, ellipsometry, and FTIR. 
Characterization of mixed monolayers  
    These monolayers were characterized with contact angles, thicknesses, and FTIR 
spectra. Contact angles were measured using Kruss Easy Drop by injecting a water 
droplet (2 µL) on a modified gold chip placed on the sample plate and contact angles 
were measured in the video window of manufacturer’s DSA software. Data shown in the 
contact angle column in Table 2 is an average of those five measurements. 
    Thicknesses of the monolayers were measured using Gaertner-Stokes ellipsometer. For 
thickness calculation, refractive indices of organic layers were assumed to be 1.46.84 
Thickness of the bare gold chip was measured first, followed by measurement of 
modified gold chips. Measurements were taken on five different arbitrary positions on the 
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* Molecular lengths calculated using ChemDraw 3D  
Table 2. Measured physical properties of monolayers 
Monolayer *Length of 
Molecule 
(calc.)(Å) 
*Length 
of 
Molecule 
11 
(calc.)(Å) 
Measured 
Thickness 
(Å) 
Measured 
Contact 
angle (deg) 
 
SAM-mb 48 (mol. 
10) 
38 32.8 ± 0.9 38 ± 1 
SAM-bb 69 (mol. 8) 38 48.2 ± 0.8 40 ± 1 
 
substrate and finally the average value was taken. The thickness of the monolayer was 
determined by subtracting the bare gold thickness from the measured one. 
 
 
 
 
 
 
 
    The spectra were acquired using Thermo Nicolet 6700. FTIR Spectra of monolayer 
and powder samples were recorded with a surface grazing angle accessory (SAGA) and 
attenuated total reflection (ATR) accessory (Smart Orbit, Thermo Electron Corporation) 
with 256 scans respectively. Area of 8mm diameter circle of the modified gold chip was 
used as an active spot for the monolayer spectra measurement. A cluster of the band 
appears in between 2800-3000 cm-1 in monolayers and solid samples are assigned to CH2 
symmetric and asymmetric stretches from backbone and ethylene glycol moieties. Band 
near 1700 cm-1 corresponds to the presence of carbonyl group in solid and monolayer 
sample. Also, Broad band near 3300 cm-1 is assigned to the stretches of both amide (-NH) 
group and hydroxyl (-OH) groups present in all the samples.  
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Figure 26. FTIR spectra of (A) compound 10, (B) compound 8; (C) mixed 
monolayer SAM-mb; (D) mixed monolayer SAM-bb.  
  (A) 
  (B) 
  (C) 
  (D) 
 
 
 
 
 
 
 
 
 
 
 
2.3.4 SPR experiments  
    The instrument Bi 2000 from Biosensing Instrument was used for SPR measurements. 
A gold chip coated with a monobiotinyl monolayer (SAM-mb) was mounted on the 
instrument, and calibrated with 1% ethanol in a PBS buffer, pH 7.4. A solution of 
streptavidin in PBS buffer (0.4 µM) was flowed onto the chip at a rate of 30 ul/min over a 
period of 2.5 min, followed by flowing the PBS buffer until a steady-state response was 
observed, and then a solution of D-biotin in PBS buffer (3 mM) was flowed onto the chip 
over a period of 25 min at the same rate. The SPR experiments on the SAM-bb were 
carried out in the same procedure. Association rate constants (kon) were determined by 
fitting the curve into most commonly used Langmuir 1:1 interaction model in OriginPro 
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2015 and competitive dissociation rate constants (koff) were determined by fitting the 
curve into an equation reported in literature74 in OriginPro 2015: 
 =  + 	 
−  −  	+ 	 
−  −  
 
2.3.5 Summaries  
    Departing from a benzene ring, one of the most commonly used scaffolds to construct 
multivalent molecules,58 we extended the structure with phenylethynyl groups to create a 
larger rigid structure, on which small sized antibody mimics can be constructed. The 
phenylacetylene chemistry used in this present study can be extended to synthesizing 
even more complicated and larger scaffolds.85 Using the biotin-streptavidin interaction as 
a model, we have demonstrated that the three arm bisbiotin ligand: (1) formed an 
intramolecular bivalent complex more stable than its intermolecular counterpart on the 
surface; (2) bound to streptavidin cooperatively. We should point out that three arm 
bisbiotin formed a very stable complex with streptavidin mainly because it reduced the 
dissociation rate significantly. This implies that an antibody mimic would increase the 
residence time (smaller koff) of a ligand interacting with its receptor, which is of 
importance in applications for drug discovery. Further studies are needed to get detailed 
information on using three arm linker as antibody mimic.  
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CHAPTER 3 
3 Site-specific chemical modification of peptides, proteins and its attachment to 
DNA thread for their translocation through solid-state nanopores 
 
3.1 Introduction  
 
3.1.1 Advancement in N-terminal modification of peptides and proteins  
    Development of protein modification strategies is an important field of research. 
Placing a synthetic group at a desired location in protein make this task even more 
challenging. Some of the methods targeting specific amino acids have already been 
discussed in chapter 1. The presence of multiple copies of same native amino acid all 
over the protein makes this strategy less effective to achieve the goal of site-specific 
modification. Cysteine being one of the rarest amino acids can be targeted to solve this 
problem.40 But, the introduction of new cysteine moiety by genetic engineering may 
sometimes affect the structure and function of proteins. For example, antibodies held 
their structure by disulfide bond formation86 and metallothioneins have multiple cysteine 
residues in their active site87. Incorporation of new cysteine residue may affect these 
properties. Sometimes there is more than one modification needed at different places of 
protein. In those cases, other than cysteine modifications new strategies are still required 
for the second modification. 
     One of the strategies that can be followed is targeting native functionalities that occur 
only once in peptide and proteins i.e. N-, C- terminus. N-terminus being nucleophilic 
provides us with the opportunities to carry out the reaction with different reagents. Here, 
some of the reagents targeting N-terminus are listed below. 
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    Pyridoxal-5-phosphate (PLP) is such a reagent which has been used to install a reactive 
ketone functional group at the N-terminus of peptides and proteins.88 The reaction 
scheme is shown below.  
First, the reaction has been optimized for different peptides and further applied to some 
of the proteins. One table is shown below for showing data for protein modification by 
PLP.  
    This PLP mediated reaction would not be effective for the N-terminal residues having 
serine, threonine, cysteine and tryptophan because they can have side reactions with 
aldehydes. Also, N-terminal proline would remain unreactive towards PLP. 
Scheme 17. N-terminal modification of twenty naturally occurring amino acids by PLP.88 
  
Table 3. Data for site-specific protein modification using PLP.88  
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    O-amino phenol is another reagent used for N-terminal peptide, protein modification 
through oxidative coupling strategy.89 The reaction scheme is shown below.  
O-amino phenol has been tested for a series of peptides and proteins showing its 
effectiveness for N-terminal modification. Data showed that oxidative coupling strategy 
is very much effective for proline residue at the N-terminal of peptides and proteins 
compared to the other 20 naturally occurring amino acids. This makes use of this reagent 
very limited.  
    Ketens have also been used for site-specific N-terminal peptides and proteins 
modification.90 The reaction scheme is shown below.  
 
 
 
 
Scheme 18. Schematic representation of oxidative coupling of O-amino phelol with A) 
aniline moiety, B) twenty naturally occurring amino acids, C) prolin residue.89 
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Great site-specificity has been achieved effectively with ketene reagent. But, conversions 
of peptides and proteins are poor. 
    Defficiencies in above mentioned examples lead us to think of a simple and effective 
strategy which should be capable of site-selectively modifying any N-terminus amino 
acid in peptides and proteins in mild condition. The progress of this strategy has been 
discussed in details later in this chapter. 
3.2 Peptide and protein sequencing using nanopores 
    Nanopores—orifices with nanometer diameters— can function as nanofluidic channels 
for the flow of ions and the transport of biomolecules. When a charged molecule is 
electrophoretically driven through the nanopore, it partially obstructs the passage of ions 
and modulates the current through the pore. Parameters derived from the current 
blockade can be used to identify the molecule and even identify structural subunits. 
Nanopore techniques are emerging as a single molecule tool for sequencing DNA,91 
detecting proteins,92 polysaccharides,93 viruses,94 with possible clinical applications95. As 
the protein nanopore DNA sequencing technology makes inroads into genomic 
research,96,97,98 a legitimate question naturally arises: can the nanopore sequence proteins 
Scheme 19. Schematic representation of N-terminal modification of peptide or protein 
by ketene compound.90 
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as well? Given the fact that even a MspA protein nanopore, which has a finer nanopore 
(0.5 nm thickness and 1.2 nm diameter) than α-hemolysin, only demonstrates a four-
nucleotide resolution91 with ~ 85% accuracy,99 it seems unlikely that ion-current 
blockade measurements will resolve individual amino acids because the amino acid 
calling will otherwise depend on sorting 204 = 160,000 different signals. A new reading 
mechanism has to be developed to achieve single amino acid residue resolution for 
protein sequencing. Electron tunneling detection has been shown to have this capability. 
Recently, we have demonstrated that individual amino acids can be identified and two 
different peptides distinguished at a single molecule level by a technique we call 
recognition tunneling, which measures tunneling currents of analytes in a ~ 2.5 nm 
nanogap with its two electrodes functionalized with recognition molecules.100 Kawai and 
coworkers have also reported the identification of amino acids and phosphorylated 
peptides by means of electron tunneling currents with either 0.5 or 0.7 nm nanogaps.101 
Thus, one can conceive of a device that integrates a tunneling gap with a solid-state 
nanopore for analyzing protein sequences. 
    Here, another primary issue has been addressed in developing the nanopore technology 
for analysis of proteins in a proteome, which is the translocation of proteins and peptides. 
While DNA is always negatively charged with uniform distribution along its phosphate 
backbone under physiological conditions, a protein can be zero, positive or negative in its 
net charge, however, it bears both positively and negatively charged side chains randomly 
distributed on its amide backbone. This makes translocating the protein 
electrophoretically challenging. Due to lack of a PCR-like techniques for analysis of 
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proteins, it is very difficult to even acquire direct evidences to prove protein 
translocation.102 Recently, Akeson and his coworkers first demonstrated that a 
recombinant ubiquitin-like protein Smt3 bearing a polyanionic peptide at its C-terminus 
was unfolded and pulled through a α-hemolysin (α-HL) nanopore by the AAA+ 
unfoldase ClpX.103 Almost at the same time, Bayley’s team reported that a thioredoxin 
protein tethered to a negatively charged oligonucleotide could also be unfolded and 
translocated through the α-HL nanopore by an applied voltage.104 These studies suggest a 
new approach to translocating proteins using a charged ‘pulling-string’ to draw the 
protein into a nanopore.  
With the ultimate goal of sequencing proteins, our initial objective has focused on 
using a recognition tunneling nanopore to identify peptides. As a matter of fact, the most 
commonly used method in proteomics is the shotgun mass spectrometry, in which 
proteins are first digested into peptides with enzymes, such as trypsin–that generates 
peptides containing only one lysine or arginine residue at their C-terminus, separated 
with liquid chromatography, and injected as charged ions into mass spectrometer for 
identification.105 While working on fabricating a fixed-gap tunnel junction in solid-state 
nanopores,106 a molecular threading strategy has been developed to facilitate 
translocation of peptides: tethering a chain molecule with a large net charge, which 
functions as a molecular thread, to the termini of peptides to make them all have the same 
sign of charge so that they can be carried over from one side to another of a nanopore by 
the threading molecule under a voltage bias. Thus, a basic requirement for the threading 
molecule is that it can readily translocate through nanopores. We chose an 
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oligonucleotide composed of 20 thymidines (referred to as PolyT20) as a negatively 
charged thread because a PolyT molecule has a well-defined structure and charge 
distribution, its translocation has been well studied,107,108 and it is also immediately 
available from commercial sources. In this present study, we have focused on developing 
a simple and effective chemistry for attaching the oligonucleotide to the N-termini of 
peptides, and demonstrating the translocation of the DNA-peptide conjugates through 
solid-state nanopores. 
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3.3 Results and Discussion 
 
3.3.1 Addition of PolyT20 to N-termini of peptides  
    We chose to functionalize the N-terminal α-amine of peptides because it is more 
nucleophilic than the carboxylate at C-terminus, susceptible of chemical modification 
with electrophilic reagents in the physiological conditions. Then, the challenge is to find 
a reagent and conditions that selectively react with the α-amine in the presence of other 
nucleophilic groups, such as ε-amine of lysine. Although there are a plethora of chemical 
methods for modification of proteins reported in the literature,110 there is a lack of 
universal chemistry to specifically modify the N-termini of peptides. To a certain degree, 
the N-terminal reactions vary with peptide sequences90 and amino acid residues at the end 
88,111 in terms of their selectivity and efficiencies. For our purpose, it is particularly 
important to have a general method to modify any N-terminal amino acid with high 
selectivity no matter what sequence it is connected to. Acylation is a commonly used 
chemical reaction in the modification of proteins, which utilizes chemical reagents such 
as carboxylic halide, carboxylic anhydride, or active ester.110 It has been reported that the 
carboxylic anhydrides can selectively react with the N-terminal amines of peptides at 
slightly basic conditions.112,113 Accordingly, we devised a process that harnesses the 
anhydride reaction to effectively introduce a bioorthogonal function to N-termini of 
peptides for the DNA attachment. As shown in Scheme 21, an azidoacetic anhydride 
reagent first reacts with a peptide bearing a lysine residue at its C-terminus, generating an 
N-azidoacetylated peptide under a slightly acidic condition (Step 1), and then the azide 
group reacts with 
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aza-dibenzocyclooctyne (ADIBO) functionalized PolyT20 through a click reaction, 
resulting in a desired DNA-peptide conjugate (Step 2). The ADIBO function—a strained 
cycloalkyne—specifically reacts with azide at a high reaction rate (k = 0.3 M-1s-1) without 
need of a copper catalyst114 (so called copper free click chemistry115). Given these 
advances in click chemistry, we paid more attention to the reaction of azidoacetic 
anhydride with peptide in high selectivity. Besides ε-amine of lysine, the acyl anhydride 
Scheme 20. Chemical reactions for attaching an oligonucleotide to N-termini of 
peptides.109 
  
  Step 1 
  Step 2 
            Table 4. Peptide sequences used in this study and their 
physicochemical properties109* 
 Sequence Mass a Net Charge 
at pH 7 
a
 
P-1 YLGEEYVK 999.49 -1 
P-2 DRVYIHPFHL 1295.68 +0.2 
P-3 EAIYAAPFAKKK 1335.76 +2 
* 
a
 Calculated using the peptide property calculator in                      
http://www.innovagen.com/custom-peptide-synthesis/peptide-
property-calculator/peptide-property-calculator.asp;  
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can react with the phenolate ion of tyrosine, sulfhydryl group of cysteine, aliphatic 
hydroxyl of serine and threonine, and imidazolyl ring of histidine as well.116 However, 
the intrinsic reactivity of these groups to an electrophile and stability of their acyl 
derivatives are all different. In most cases, the reactive groups involved in the acylation 
are the α- and ε-amine, imidazolyl ring, and to a lesser extent, –SH and –OH. The 
thioester and ester from acylation of cysteine, tyrosine, serine and threonine residues can 
be reversed to the original groups.117 In an aqueous solution, these functional groups have 
distinguishable acid dissociation constants (pKa): for example, an average pKa value for 
ε-amine of lysine in proteins is 10.5, for α-amine of the N-terminus is 7.7.118 Because a 
protonated amine is not reactive, this discrepancy gives us a room to tune the selectivity 
of the acylation reaction by changing the pH and, in turn, the protonated states of these 
amines (Step 1 in Scheme 21). To achieve high selectivity for the α-amine, indeed, we 
chose a slightly acidic condition for the acylation reaction, instead of the basic.  
    We have studied three representative short peptides (designated as P-1, P-2, and P-3, 
respectively, in Table 4) for the reactions shown in Scheme 21.109 The sequences and 
calculated physicochemical properties of these peptides are listed in Table 4. In 
particular, P-1 and P-3 contain different numbers of lysine (K) and no histidine (H), and 
P-2 has two histidines and no lysine. Each of them carries a different net charge at neutral 
pH. Circular Dichroism (CD) showed that they took a random conformation in aqueous 
solution, whereas PolyT20 adopted an organized right-handed helical conformation so that 
it may provide an entropic advantage for threading into a nanopore. We began with P-1, a 
peptide that mimics a trypsin digest. First, we compared the anhydride with another 
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commonly used acylating reagent N-hydroxysuccinimidyl (NHS) ester for their 
selectivity. The NHS azidoactate reacted with P-1 at pH 6.7, but produced two products 
that were characterized as a peptide modified by one and two azidoacetyl (N3CH2CO-) 
groups by MALDI mass spectrometry. In general, the NHS ester may preferentially react 
  (A)   (B) CID of peak 1 
  (C) CID of peak 2   (D) CID of peak 3 
Figure 27. HPLC and Mass analysis of azidoacetic anhydride reacting with P-1: (A) RP 
HPLC chromatograms of (i) starting materials and (ii) the reaction mixture at pH 6.7; (B) 
Tandem mass spectrum of peak 1 in (A); (C) Tandem mass spectrum of peak 2 in (A); 
(D) Tandem mass spectrum of peak 3 in (A); Inserts in B, C, and D are calculated 
fragment ions of the corresponding peptides.109 
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with the lysine amine. Mentinova et al have showed the preference for the N-terminal 
amine only when pH was ~ 5.119 based on these results, we chose azidoacetic anhydride 
as an acylating reagent (see Experimental Methods for its synthesis). Initially, the 
acylation reaction was carried out with P-1 at a concentration of 0.4 mM and azidoacetic 
anhydride at 1.2 mM in a sodium acetate buffer, pH 6.7 at 0 °C, and monitored by reverse 
phase (RP) HPLC. Retention time (tR) of each starting material was determined by a 
separate HPLC run (Figure 27, A-i). After 15 min, three new peaks appeared in the 
HPLC chromatogram, labeled as 1, 2 and 3 in red (Figure 21, A-ii). The peak 1 has a 
shorter retention time (tR) than P-1; in contrast, both peak 2 and 3 have longer retention 
times compared to P-1. The ratio of these three peaks was 5:89:6, determined by their 
chromatographic peak areas. We separated these individual products and characterized 
them with MALDI and tandem mass spectrometry. Peak 1 was determined as a product 
 
    Table 5. Effects of reaction conditions on the selectivity  
    of azidoacetic anhydride109 
pH Time (min) Conversion of 
P-1 
Acylating ratio* (α 
to ε amine) 
5.5 15 15% 100 : 0 
6.1 15 61% 98.9 : 1.1 
6.7 15 85% 96 : 4 
6.7 60 97% 91 : 9 
* calculated based on areas of peak 2 and 3 
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resulting from adding a 43 Da mass unit to P-1. In its CID spectrum (Figure 27, B), the 
mass of observed y ions (y3 to y7) matches those calculated from P-1 without 
modification from its C-terminus to one next to the N-terminus, indicating that the 
addition took place at the N-terminus. The N-terminal modification was further 
confirmed by observed b ions (Figure 27, B), every of them matching up with the mass 
derived from a P-1 fragment plus an additional 42 Da. The 42 Da mass may be explained 
by substituting an acetyl group for one hydrogen of the α-amine (CH3CO - H). To prove 
this substitution, we carried out a reaction of acetic anhydride with P-1 under the same 
conditions, finding out that the major product (98%) had the same tR and mass as the 
peak 1 (Figure 28). This acetyl byproduct was unexpected, albeit only ~ 5 % in the 
product mixture (and not reactive in the following reaction). Further investigation is 
required to determine its origin. Peak 2, which was the major product, has a mass of 
Figure 28. HPLC and Mass analysis of acetic anhydride reacting with P-1: (A) RP 
HPLC chromatogram of reaction mixture at pH 6.7; (B) MALDI mass spectrum of the 
acetylated product [calculated mass for C49H72N9O16 (MH
+): 1042.50, found: 
1042.51].109 
  
  (B)   (A) 
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1083.5 Da, corresponding to mono-azidoacetylated P-1. By analyzing its CID spectrum, 
peak 2 was identified as a product of α-amine azidoacetylated P-1 (Figure 27, C). Peak 3 
has a mass of 1166.5, corresponding to the addition of two azidoacetyl groups to P-1, and 
its CID spectrum indicates that it is a product of both N-terminal and ε-lysine amine 
azidoacetylated P-1 (Figure 27, D). This study also showed that the tyrosine residue did 
not react with azidoacetic anhydride below neutral pH. Next, we studied effects of pH 
and reaction time on products by means of the HPLC analysis, and the results are listed in 
Table 5. First of all, at pH below 7, azidoacetic anhydride reacted with the N-terminal 
amine with high selectivity (> 90%). It increased by decreasing the pH, but the 
conversion of P-1 to products was reduced as well. Extending the reaction time increased 
the conversion rate of peptide to products but also reduced the selectivity and more 
byproducts were produced. Overall, the reaction of azidoacetic anhydride with P1 can 
achieve > 90% selectivity and a > 90% conversion rate of starting material to product.  
    In turn, we examined the possible reaction of azidoacetic anhydride with histidine. P-2 
was a peptide adopted from hormone angiotensin II, carrying two histidine residues and 
no lysine in its sequence. At pH 6.7, it reacted with azidoacetic anhydride, resulting in 
three products (Figure 29, A-i, labeled as 1, 2, 3 in red). Their ratio was determined as 91 
: 5 : 4, in which peak 1 was a major product. The CID mass analysis confirmed that the 
peak 1 was a product of N-terminal azidoacetylated P-2 (Figure 30, A), both peak 2 and 3 
were products of P-2 with one of its histidines residue azidoacetylated. When lowering 
the reactant ratio to 3:1 between azidoacetic anhydride and P-2, the conversion rate was 
reduced to 17%, but the product ratio between peak 1 and 2 was 91:9 and peak 3 did not 
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appear 
(Figure 29,A-ii). At pH 5.5, the peak 2 then became a major product (Figure 29, B-iii). 
This is probably because the imidazolyl ring of histidine has a lower pKa than the N-
terminus amine so that it is more reactive at the low pH. Unexpectedly, the azidoacetyl 
group on the imidazolyl ring could not be removed by the base treatment (even with 
concentrated ammonia).  
    To further explore limitation of the acylation reaction, we studied the reaction of 
azidoacetic anhydride with P-3, which has three lysine residues at its C-terminus. As a 
result, P-3 yielded a mixture of five new products at pH 6.7, labeled as 1, 2, 3, 4, 5 in red, 
respectively (Figure 29, B-i). We have assigned these peaks to their corresponding 
products in the same way as was done for P-1. The peak 1 is a product resulting from 
Figure 29. RP HPLC profiles of azidoacetic anhydride reacting with (A) P-2 and (B) 
P-3 at different pH and reaction time.109 
  
  (A)   (B) 
 88 
 
acetylating P-3 at the N-terminus, the peak 2 is a product of P-3 with one lysine 
azidoacetylated, peak 3 is P-3 with N-terminus azidoacetylated, peak 4 and 5 are P-3 
with two lysine azidoacetylated. We determined the ratio of these peaks as 1:2:3:4:5 = 7.1 
: 2.2 : 73.0 : 5.0 : 12.7. Again, the N-terminal azidoacetylated product (peak 3) was the 
major product. This result shows that the azidoacetylating reaction can selectively take 
place at the N-terminal amine of a peptide even when the peptide contains multiple lysine 
residues. The selectivity can be improved by lowering pH. As shown in Figure 29, B-ii, 
the selectivity increased to ~ 98% at pH 5.5, but the conversion rate of the peptide-to-
product was reduced to 19% from 75% at pH 6.7. By comparing the results shown in B-ii 
with B-iii of Figure 29, it indicates that extending the reaction time increased the 
Figure 30. Mass analysis of products from P-2 reacting with azidoacetic anhydride: 
(A) Tandem mass spectrum of peak 1[calculated mass for C64H91N20O15 (MH
+): 
1379.696, found: 1379.687,]; (B) Tandem mass spectrum of peak 2 [calculated mass 
for C64H91N20O15 (MH
+): 1379.696, found: 1379.708,].109 
  
  (A)   (B) 
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conversion rate of peptide-to-product, but also reduced the selectivity. The above-
discussed studies indicate that azidoacetic anhydride can rapidly react with α-amine with 
high selectivity at a slightly acidic condition, suitable for labeling the N-termini of trypsin 
digests.  
    Next, we studied the reaction of azidoacetylated peptides with PolyT20 (Step 2 in 
Scheme 21).109 ADIBO-T20 was synthesized by reacting ADIBO-NHS ester with PolyT20 
bearing a C12 amino modifier at its 5’ end in a phosphate buffer pH 8, and purified by 
RP HPLC. It spontaneously reacted with each of N-azidoacetylated peptides when they 
were mixed in a TEAA buffered solution (pH 7), resulting in desire peptide-PolyT20 
conjugates, designated as P-1-T20, P-2-T20, and P-3-T20 (characterized by MALDI mass 
spectrometry). The HPLC analysis indicated that these peptides were quantitatively 
converted to the corresponding peptide-PolyT20 conjugates with no detectable 
byproducts. Nonetheless, the times to complete these reactions were different among 
these peptides, 45 min for reacting with N-azidoacetylated P-1, 20 min with 
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azidoacetylated P-2, 10 min with azidoacetylated P-3. The reaction rates seem to 
correlate with net charges of these peptides (see Table 4). The more positively charged P-
3 reacted with negatively charged PolyT20 fastest, the negatively charged P-1 the slowest, 
and with P-2 (which has a smaller positive charge) intermediate. We also noticed that the 
product peaks are split into two or broadened in the HPLC chromatograms. This is 
Figure 31. RP HPLC profiles of peptide-DNA conjugates monitored at 260 nm 
wavelength: (A) reaction mixture of P-1-T
20  (B) reaction mixture of P-2-T20  (C) 
reaction mixture of P-3-T
20 
.
109 
  
  (A) 
  (B)   (C) 
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because the ADIBO-azide reaction produces a regioisomeric mixture of the triazole 
connection. In our case, the peptides were connected to either position 1 or 3 of the 
triazole ring (see Scheme 21. We also characterized conformations of these conjugates 
with CD spectroscopy (Figure 32). At the first glimpse, these CD spectra are dominated 
by signature of DNA. Compared to polyT20 modified with ADIBO, the negative peaks (at 
~ 250 nm) of the conjugates are reduced, with an order of their intensities: ADIBO-T20 > 
P-2-T20 ≈ P-1-T20-3’ > P-1-T20 > P-3-T20. This may reflect increase in the lysine residue 
at the C-termini interacting with the phosphate backbone when the peptide is conjugated 
to the 5’ end of DNA, resulting in diminished helical structure. P-3-T20 that contains 
three lysine residues at its C-termini has the strongest interaction with PolyT20.  
 
 
Figure 32. CD spectra of PolyT20-peptdie conjugates. The measurement was carried out 
with each analyte of a 100 µm concentration in a sodium acetate buffer, pH 6.7. Each 
curve was an average of 4 scans with the buffer as a reference.109 
 92 
 
3.3.2 Site-specific protein modification using azidoacetic anydride 
    We also studied effectiveness of azidoacetic anhydride in site-specific modification of 
couple of proteins such as lysozyme and insulin. The acylation reaction was carried out 
with lysozyme at a concentration of 0.4 mM and azidoacetic anhydride at 1.2 mM in a 
sodium acetate buffer, pH 6.7 at 0 °C, and monitored by reverse phase (RP) HPLC. After 
15 min, two new peaks appeared in the HPLC chromatogram, labeled as 1 and 2 (Figure 
33, A). The ratio of these two peaks was 83:17, determined by their chromatographic 
peak areas. We separated these individual products and characterized them with MALDI. 
Peak 1 was determined as a product and peak 2 as doubly modified product. But, further 
studies need to be carried out to confirm modification occurred at N-terminus of protein. 
    To further explore effectiveness of the acylation reaction, we studied the reaction of 
azidoacetic anhydride with insulin protein. As a result, insulin yielded a mixture of three 
new products at pH 6.7, labeled as 1, 2, 3 respectively (Figure 23, B). We have assigned 
these peaks to their corresponding products in the same way as was done for lysozyme. 
The peak 1 and peak 2 are a product resulting from mono acetylation insulin and peak 3 
corresponds to double modification. This reaction needs to be further optimized to get a 
better selectivity. Also, tandem mass spectrometry studies need to be peroformed to 
indentify modification of insulin occurs at N-terminus.  
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3.3.3 Developing chemistry to ligate different charged molecules on N- and C-
termini of peptide 
    One new conjugate having opposite charges on N- and C-termini of peptide has been 
synthesized. DNA thread (T10) was attached to the N-termini and C-termini had a peptide 
having 10 histidine residues (H10). Histidines are expected behave as neutral molecule 
near pH 7 and is supposed to have positive charges below pH 6. Therefore, a pH gradient 
within the nanopore will lead to a construct (T10-P-1-H10) where two opposite charges 
will be generated on both the end of peptide. 
Figure 33. RP HPLC profiles of azidoacetic anhydride reacting with (A) lysozyme 
and (B) insulin at pH 6.7. 
  (A)   (B) 
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Scheme 21. Scheme for synthesis of opposite charged molecules with peptide (1) P-1 
modification by NHS-transcyclooctene at the lysine side chain; (2) Modification of N-
termini of peptide having 10 histidine residues (H10) with NHS-methyl tetrazine; (3) 
Synthesis of P-1-H10; (4) Synthesis of T10-P-1-H10  
    Synthesis of T10-P-1-H10 is shown in scheme 21. First, P-1 was modified by NHS-
ester of trans cyclooctene at the lysine side chain. This reaction was carried out in acetate 
buffer (pH 8) over a period of 1hr. Starting material (P-1) was consumed and one new 
peak was generated with 6.8 min retention time which was characterized to be the peptide 
modified product (P-1-Transcyclooctene) (Figure 34 ). Then, H10 was modified at the N-
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terminus by reacting H10 with NHS ester of methyl tertrazine. HPLC diagram showed 
that a new peak at 15 min retention was H10-Tetrazine.  
    Next, P-1 was coupled to H10 to give P-1-H10 conjugate. This reaction was performed 
in TEAA buffer (pH 7) for 30 min. H10-Tetrazine was used in excess amount in the 
reaction so that P-1-Transcyclooctene got consumed totally to give the new conjugate. 
Finally, P-1-H10 was reacted to T10-ADIBO to give T10-P-1-H10. T10-ADIBO was used in 
excess in the reaction and it took 45 min to get the reaction completed. Product peak was 
Figure 34. HPLC diagram for synthesis of various conjugates (A) P-
Transcyclocotene; (B) H10-Tetrazine; (C) P-1-H10; (D) T10-P-1-H10  
  (A)   (B) 
  (C)   (D) 
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found to have 9.8 min of retention time. All the products were characterized by MLADI-
TOF. 
3.3.4 Translocation of peptide-PolyT20 conjugates through solid-state nanopores  
    We devised a setup as illustrated in Figure 33-A to measure the molecular 
translocation, following a procedure we previously reported on measurements of DNA 
translocation through solid-state nanopores.120 Final concentration of analyte solution ~ 
1.0 µM. All of measurements were carried out in a 0.4 M KCl electrolyte solution 
buffered with 1.0 mM phosphate, pH 7.4. Figure 33-B shows three typical nanopores we 
used for the the translocation measurement. Their sizes and shapes are slightly different 
from one another, determined by TEM imaging. With each individual nanopore, we were 
able to finish measurements on translocation of a peptide-PolyT20 conjugate as well as its 
parent peptide and oligonucleotide before it became clogged. In a typical translocation 
experiment, we began with measuring following an order of PolyT20, peptide-PolyT20 
conjugate, and then peptide. Between the measurements, the nanopore was rinsed with 
 97 
 
the electrolyte solution to remove any analyte residue and restore it to the original 
conductive state. The raw data generated by these nanopores are shown in Figure 33-C 
(Pore-1), D (Pore-2), and E (Pore-3), respectively. We immediately notice that there was 
no translocation of peptides because neither negatively charged P-1 nor positively 
charged P-2 and P-3 created spikes of current blockades (Figure 33, C-i, D-i, and E-i) 
Figure 35. (A) Schematic illustration of a nanopore device for translocation 
measurements; (B) TEM images of the nanopores used for translocation and their 
physical parameters; (C) Ionic current traces of i: P-1, ii: PolyT20, iii: P-1-T20 in Pore-
1;(D) Ionic current traces of i: P-2, ii: PolyT20, iii: P-2-T20 in Pore-2; (E) Ionic current 
traces of i: P-3, ii: PolyT20, iii: P-3-T20 in Pore-3 (Bias: 500 mV; Analyte concentration: 
~ 1.0 µM).109  
  (A)   (B) 
  (C)   (D)   (E) 
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under our measurement conditions. As expected, PolyT20 was readily translocated 
through these nanopoes (Figure 33, C-ii, D-ii, and E-ii), and so do the peptide-PolyT20 
conjugates (Figure 33, C-iii, D-iii, and E-iii). These current spikes were analyzed by 
means of the OpenNanopore software and each spike was assigned a dwell time and a 
current-blockade value. Median values of dwell time for all the samples (PolyT20 and 
conjugates) are reported in the Table 6. The distributions change from pore to pore, as 
can be seen by comparing values for PolyT20 between the three pores. However, by most 
measures, we see the somewhat surprising result that the conjugates translocate more 
rapidly, or on about the same time scale, as PolyT20 alone (data for Pores 1 to 3). 
    Data for the current blockades give a clearer picture of the differences between PolyT20 
and its peptide conjugates than the widely distributed translocation times. In order to 
compare data for the various samples, each blockade-current data set was normalized by 
its maximum value and plotted into a normalized histogram, as shown in Figure 34. We 
consider first the PolyT20 data. All the data sets were fitted by a double-peaked Gaussian 
function with R2 > 0.90 (Figure 34), with a major peak at ∆I/I0 in the range of 0.15 to 0.2 
and a minor peak in the range of 0.5 to 0.6. Similar features have been reported for DNA 
translocation through α-hemolysin pores where they were explained by the so-called 
Table 6. Dwell times of PolyT20 and its peptide conjugates in different 
nanopores.109  
 Pore 1 Pore 2 Pore 3 
Sample P-1-T20 PolyT20 P-2-T20 PolyT20 P-3-T20 P-1-T20 
Median (µS) 60 70 60 90 70 70 
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Christmas-tree effect.121,122 When a single stranded DNA is translocated, it can thread 
either via its 5’- or its 3’-end into a nanopore. Meller and co-workers demonstrated by 
all-atom molecular dynamics (MD) that DNA bases in a stretched conformation 
preferably tilt toward the 5’-end in a confined pore.121 This is because all of nucleosides 
in DNA have a β configuration, in which a nucleobase stays at the same side with the 5’-
hydroxyl group of a nucleoside on the deoxyribose ring. As a result, 
DNA translocation with threading through the 3’-end should be more frequent and less 
blockaded than through the 5’-end (just as a Christmas tree can be moved into a door 
more easily from its trunk end than from its tip). Based on this hypothesis, we may assign 
the major blockade peaks (at smaller current values) for translocation events through the 
3’-end threading. From the literature, we found a similar trend in the translocation of 
Figure 36. Histograms of fractional current blockades for PolyT20 and its peptide 
conjugates at bias 500 mV. (A) Translocation through Pore 1; (B) Translocation through 
Pore 2; (C) Translocation through Pore 3. Blue: PolyT20, Red: peptide conjugate; ∆I = I0 
(open pore current) – I (blocked pore current). The dark yellow lines in histograms are 
the Gaussian fitting curves and N = number of events.109 
 
  (A)   (B)   (C) 
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PolyA20 through a α-HL nanopore.
123 Thus, when a short peptide is tethered to the 5’-end 
of PolyT20, it reduces the probability of threading through the 5’-end. This accounts for 
the observation that the large current blockades were diminished in the translocation of 
the peptide-PolyT20 conjugates compared to the corresponding PolyT20. P-3-T20 displays 
a large tail following its major peak (Figure 34-C) and also translocates more slowly 
(Table 6) than the other two conjugates just mentioned above. This might be explained by 
the conformational structure of the peptide-PolyT20 conjugate. The CD spectrum (Figure 
32) shows that the peptide P-3 has stronger interactions with the backbone of PolyT20 in 
the conjugate than other two peptides, which may result in looped structures. When a 
conjugate with such a structure translocates through the nanopore, it would create larger 
blockade currents, as observed. 
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3.4 Experimental procedure 
 
3.4.1 General information 
    Chemicals were purchased from Sigma-Aldrich and anhydrous organic solvents were 
Aldrich’s Sure/SealTM. ADIBO-NHS ester was purchased from Click Chemistry Tools. 
Peptides were custom synthesized by CPC Scientific (San Jose, C, USA) and 
oligonucleotides (PolyT20) with a C12 amino modifier at its 5’ end by IDT (Integrated 
DNA Technologies). 1H and 13C NMR spectra were recorded at 400 MHz (1H), 100 MHz 
(13C), respectively. Chemical shifts are given in parts per million (ppm) on the delta scale 
(δ) and are referred to the solvent residual peak. HPLC analysis and purification were 
carried out in Agilent 1100 series equipped with a UV detector and a fraction collector. A 
Zorbax Eclipse Plus C18 column (4.6 x 150 mm, particle size 5 µm) from Agilent was 
used for the reversed phase HPLC. MALDI-TOF analysis was performed on Voyager-DE 
STR instrument.109 
Azidoacetic anhydride synthesis  
The synthesis was carried out following a method reported in literature with 
modification.124 N,N’-Dicyclohexylcarbodiimide (DCC, 204 mg, 0.98 mmol) was added 
to a solution of 2-azidoacetic acid (200 mg, 1.98 mmol) in anhydrous tetrahydrofuran (2 
ml). The solution was stirred for 2 h and 15 min, during which the precipitate was 
gradually produced, and filtered. The filtrate was concentrated by rotary evaporation, 
giving azidoacetic anhydride (150 mg, 42%) as a colorless liquid. 1H NMR (400 MHz, 
CDCl3) δ: 3.85 (s, 4H); 
13C NMR (100 MHz, CDCl3) δ: 168.3, 50.0. 
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General procedure for reaction of azidoacetic anhydride with peptide (P-1, P-2, and 
P-3)  
A solution of azidoacetic anhydride in acetonitrile (5 mM, 3.0 µL) was added to a 
solution of peptide in a 50 mM sodium acetate buffer (0.5 mM, 10 µL) with a predefined 
pH value in an eppendorf tube. The reaction was kept at 0 °C for 15 min, followed by the 
addition of water (10 µL), and remaining the reaction in ice for another 10 min for 
completely terminating the reaction. RP HPLC, with a gradient of 5 to 45% B in 25 min 
(solvent A: 0.1 M TEAA buffer, pH 7.0; solvent B: acetonitrile), was used to monitor the 
reactions and separate products. 
Functionalization of PolyT20 with ADIBO (ADIBO-T20)  
A solution of PolyT20 containing a C12 amino modifier at its 5’-end (1 mM, 10 µL) in 
water and DBCO-NHS ester in DMSO (15 mM, 80 µL) were mixed in a phosphate 
buffer (30 µL, pH 8). The solution was shaken for 20 min at room temperature. The 
product was purified by RP HPLC in a Zorbax Eclipse Plus C18 column (4.6 x 150 mm, 
particle size 5 µm) with a gradient of 10 to 60% B in 25 min (solvent A: 0.1 M TEAA 
buffer, pH 7.0; solvent B: acetonitrile). MALDI-TOF-MS calc. for 
[C233H304N42O143P20](M+H): m/z 6600.58; found: 6603.34. 
Reaction of N-azidoacetylated P-1 with ADIBO-T20 (P-1-T20)  
A solution of N-azidoacetylated P-1 (30 µM, 15 µL) in a TEAA buffer (50 mM, pH 7) 
was mixed with ADIBO-T20 (30 µM, 15 µL) in the TEAA buffer (50 mM, pH 7), and 
shaken at room temperature for 45 min. RP HPLC analysis showed the starting material 
was consumed. The product was purified by RP HPLC i
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column (4.6 x 150 mm, particle size 5 µm) with a gradient of 10 to 60% B in 25 min 
(solvent A: 0.1 M TEAA buffer, pH 7.0; solvent B: acetonitrile). After lyophilization, the 
product was given as a white powder. MALDI-TOF-MS calc. for [C282H374N54O159P20] 
(M+H): m/z 7683.12; found: 7684.72. 
Reaction of N-azidoacetylated P-2 with ADIBO-T20 (P-2-T20)  
A solution of N-azidoacetylated P-2 (30 µM, 15 µL) in a TEAA buffer (50 mM, pH 7) 
was mixed with ADBCO-T20 (30 µM, 25 µL) in the TEAA buffer (50 mM, pH 7), and 
shaken at room temperature for 20 min, purified by RP HPLC under the same conditions 
as did P-1-T20. After lyophilization, the product was given as a white powder. MALDI-
MS calc. for [C297H394N62O158P20] (M+H): 7979.31; found: 7978.64). 
Reaction of N-azidoacetylated P-3 with ADIBO-T20 (P-3-T20)  
A solution of N-azidoacetylated P-3 (30 µM, 15 µL) in a TEAA buffer (50 mM, pH 7) 
was mixed with ADIBO-T20 (30 µM, 15 µL) in the TEAA buffer (50 mM, pH 7), and 
shaken at room temperature for 10 min, purified by RP HPLC under the same conditions 
as did for P-1-T20. After lyophilization, the product was given as a white powder. 
MALDI-MS calc. for [C299H406N60O160P20] (M+H): m/z 8019.39; found: 8020.58. 
Reaction of azidoacetic anhydride with lysozyme  
A solution of azidoacetic anhydride in acetonitrile (5 mM, 3.0 µL) was added to a 
solution of peptide in a 50 mM sodium acetate buffer (0.5 mM, 10 µL) with a predefined 
pH value in an eppendorf tube. The reaction was kept at 0 °C for 15 min, followed by the 
addition of water (10 µL), and remaining the reaction in ice for another 10 min for 
completely terminating the reaction. RP HPLC, with a gradient of 25 to 55% B in 25 min 
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(solvent A:0.1% TFA in water,; solvent B: 0.09% TFA in 80% acetonitrile/ 20% water), 
was used to monitor the reactions and separate products. 
Reaction of azidoacetic anhydride with insulin  
A solution of azidoacetic anhydride in acetonitrile (5 mM, 3.0 µL) was added to a 
solution of peptide in a 50 mM sodium acetate buffer (0.5 mM, 10 µL) with a predefined 
pH value in an eppendorf tube. The reaction was kept at 0 °C for 15 min, followed by the 
addition of water (10 µL), and remaining the reaction in ice for another 20 min for 
completely terminating the reaction. RP HPLC, with a gradient of 10 to 55% B in 25 min 
(solvent A:0.1% TFA in water,; solvent B: 0.09% TFA in 80% acetonitrile/ 20% water), 
was used to monitor the reactions and separate products. 
Synthesis of P-1-Trans cyclooctene  
A solution of NHS-Trans cyclooctene in acetonitrile (5 mM, 3.0 µL) was added to a 
solution of peptide in a 50 mM sodium acetate buffer (0.5 mM, 10 µL) with pH 8 in an 
eppendorf tube. The reaction was kept at room temperature for 1 h. RP HPLC, with a 
gradient of 10 to 45% B in 25 min (solvent A: 0.1 M TEAA buffer, pH 7.0; solvent B: 
acetonitrile), was used to monitor the reactions and separate products. MALDI-TOF-MS 
calc: m/z 1235.51; found: 1236.38. 
Synthesis of H10-Tetrazine  
A solution of NHS-Tetrazine in acetonitrile (5 mM, 3.0 µL) was added to a solution of 
peptide in a 50 mM sodium acetate buffer (0.5 mM, 10 µL) with pH 6.7 in an eppendorf 
tube. The reaction was kept at room temperature for 20 min. RP HPLC, with a gradient of 
10 to 40% B in 25 min (solvent A:0.1% TFA in water,; solvent B: 0.09% TFA in 80% 
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acetonitrile/ 20% water), was used to monitor the reactions and separate products. . 
MALDI-TOF-MS calc: m/z 1601.23; found: 1602.44. 
Synthesis of P1-H10  
A solution of  P-1-Trans cycloctene (20 µM, 20 µL) in a TEAA buffer (50 mM, pH 7) 
was mixed with H10-Tetrazine (20 µM, 25 µL) in the TEAA buffer (50 mM, pH 7), and 
shaken at room temperature for 30 min. The product was purified by RP HPLC in a 
Zorbax Eclipse Plus C18 column (4.6 x 150 mm, particle size 5 µm) with a gradient of 10 
to 50% B in 25 min (solvent A: 0.1 M TEAA buffer, pH 7.0; solvent B: acetonitrile). 
After lyophilization, the product was given as a white powder. . MALDI-TOF-MS calc: 
m/z 2836.18; found: 2837.20. 
Synthesis of T10-P1-H10  
A solution of  T10-ADIBO (25 µM, 25 µL) in a TEAA buffer (50 mM, pH 7) was mixed 
with H10-Tetrazine (25 µM, 15 µL) in the TEAA buffer (50 mM, pH 7), and shaken at 
room temperature for 30 min. The product was purified by RP HPLC in a Zorbax Eclipse 
Plus C18 column (4.6 x 150 mm, particle size 5 µm) with a gradient of 10 to 50% B in 25 
min (solvent A: 0.1 M TEAA buffer, pH 7.0; solvent B: acetonitrile). After 
lyophilization, the product was given as a white powder. . MALDI-TOF-MS calc: m/z 
5978.50; found: 5980.38. 
3.4.2 Tandem mass spectrometry  
Collisional-induced dissociation (CID) and subsequent mass analysis of modified 
peptides were carried out on a Bruker MaXis 4G quadrupole-time-of-flight (Q-TOF) 
mass spectrometer equipped with a microflow nebulizer electrospray ionization (ESI) 
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source operated in positive ion mode. HPLC-purified peptide samples were diluted to a 
final concentration of approximately 20 µM in a 50/50 mixture of acetonitrile/water 
containing 0.1% (v/v) formic acid. Prior to analysis, the TOF mass analyzer was 
externally calibrated with a tuning mixture supplied by Agilent containing 10 species of 
varying but equally spaced masses from 118 to 2722 Da. Peptide solutions were infused 
into the ion source by syringe pump at a rate of 1.0 µL/min. The end plate offset and 
capillary were set to potentials of 500 V and 4,500 V, respectively. The nebulizer gas and 
the dry gas (both N2) were set to 1.4 Bar and 4.0 L/min, respectively, and the dry gas 
temperature was set to 220 °C.  The RF amplitude on ion funnel 1 and the multipole were 
both set to 400 Vpp.  No in-source CID energy was used.  Quadrupole ion energy was set 
to 3.0 eV. Precursor ions were selected with a m/z width of 2 and imparted enough energy 
(usually 10 – 40 eV) to diminish the relative abundance of the precursor ion to less than 
5%. Spectral digitzation was set to a rate of 4 GHz and individual TOF transients were 
summed and recorded at a rate of 1 Hz. After equilibration and spray stabilization, each 
mass spectrum was recorded for 1.5 minutes then averaged into a single spectrum. 
3.5 Summaries  
The objective of this present study was to develop simple and effective chemistry to 
functionalize peptides with a charged threading molecule to facilitate their translocation 
through nanopores. We have harnessed an acylation reaction for rapid introduction of an 
orthogonal azido function to N-termini of peptides, which allowed us to quantitatively 
attach charged oligonucleotides to peptides using a click reaction without the need of 
separating the intermediate product. At pH ~ 6.7 and 0 °C, azidoacetic anhydride quickly 
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reacted with the α amine of a peptide containing one lysine residue with > 90% 
selectivity, and the side reaction with imidazolyl ring of histidine can also be reduced to 
minimum. Thus, our chemistry should be practical for use in preparing peptides sample 
obtained from trypsin digests for nanopore analysis. The selectivity is less (~ 80%) in a 
peptide containing three lysine residues, so further improvements are required if the 
method is to be applied more widely to peptides from other sources.  
Furthermore, we have shown that the peptide-PolyT20 conjugates can effectively 
translocate through solid-state nanopores, which lays down a foundation for us to develop 
a technique for analysis of proteins using nanopores. Our data indicate that the peptide-
PolyT20 conjugates preferably enter the nanopore from the 3’ end of PolyT20. As a result, 
we conclude that an oligonucleotide can be used as a molecular thread to carry peptides 
through solid-state nanopores. While the sensitivity of ion-current measurements is 
unlikely to be adequate for de novo sequencing, it is clear that structural aspects of the 
conjugates can be probed. We hope to integrate this technology with recognition 
tunneling in order to explore the possibility of sequencing with single amino acid 
resolution in the future.100  
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